Relaxin-2 fusion protein analogs and methods of using same
Engineered relaxin-2 fusion proteins with improved pharmacokinetic properties address the limitations of relaxin-2 by extending half-life and solubility, facilitating more effective treatment of related diseases with enhanced stability and activity.
Patent Information
- Application Number
- JP2024527767
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-11
- Filing Date
- 2022-11-11
- Publication Date
- 2024-11-21
AI Technical Summary
Relaxin-2 exhibits strong antifibrotic activity but has a limited in vivo half-life, requiring frequent administration and is difficult to synthesize due to low solubility and complex cysteine bridge formation, leading to low yields of active peptides.
Development of engineered relaxin-2 fusion proteins with improved pharmacokinetic properties, comprising specific peptide sequences connected by a linker peptide, which can include IgG Fc for enhanced stability and half-life, and are easier to manufacture.
The fusion proteins demonstrate extended in vivo half-life, improved solubility, and increased biological activity, allowing for more effective treatment of relaxin-2-related diseases with reduced frequency of administration.
Smart Images

Figure 2024543455000001 
Figure 2024543455000002 
Figure 2024543455000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 263,917, filed November 11, 2021, the entire disclosure of which is incorporated herein by reference.
[0002] Sequence Listing Reference This application has been submitted electronically in ASCII format and contains a Sequence Listing, which is incorporated herein by reference in its entirety (this ASCII copy, created on November 11, 2022, is entitled "TECW-002_SL_ST26_2022-11-11" and is 284,217 bytes in size).
[0003] The present disclosure provides relaxin-2 fusion protein analogs with improved pharmacokinetic properties, methods for making these fusion proteins, and methods of using these fusion proteins to enhance relaxin-2-related activity and treat or prevent relaxin-2-related diseases in a subject. [Background technology]
[0004] Relaxin-2 exhibits strong antifibrotic activity. In damaged tissues, fibroblast activation and proliferation leads to increased collagen production and interstitial fibrosis. Cardiac fibrosis is increased by biomechanical overload and affects ventricular dysfunction, remodeling, and arrhythmogenesis. However, due to the limited in vivo half-life of relaxin, patient treatment must be repeated every 14-21 days, whereby compound administration must be performed as a continuous infusion for at least 48 hours. Furthermore, the synthesis of relaxin-2 is difficult. Due to the low solubility of the B chain and the requirement of a cumbersome and specific introduction of a cysteine bridge between the A and B chains, the yield of active peptide obtained by these methods is extremely low.
[0005] There is a need for engineered relaxin-2 analogs that have longer half-lives and are easier to manufacture. Summary of the Invention
[0006] The present disclosure provides fusion proteins that are engineered relaxin-2 analogs with improved pharmacokinetic properties. The present disclosure also provides methods of using these fusion proteins to enhance relaxin-2-related activity and treat or prevent relaxin-2-related disorders in a subject.
[0007] Provided herein is a fusion protein comprising, from N-terminus to C-terminus, a first peptide, a linker peptide, and a second peptide, wherein the first peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO:7, and the second peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO:9, or wherein the first peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO:9 and the second peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO:7, the linker peptide comprises an amino acid sequence having 12-15 amino acids, including 2-5 acidic amino acids and 10-13 non-acidic amino acids, and the fusion protein has a pI of 6.0-8.2.
[0008] In some embodiments, the linker peptide is R1R1R1R2R1R1R1R2R1R1R1R2R1 (SEQ ID NO: 195), R1R1R1R2R1R1R1R2R1R1R1R2R1R1R1 (SEQ ID NO: 196), R1R1R2R1R1R2R2R1R1R1R2R1R1R2R1R1 (SEQ ID NO: 197), R1R1R1R2R2R1R1R1R2R2R1R1R1 (SEQ ID NO: 198), and R1R1R2R1R2R1R1R2R1R2R1R1R1 (SEQ ID NO: 199), R1 is a non-acidic amino acid and R2 is an acidic amino acid.
[0009] In some embodiments, the acidic amino acid(s) is aspartate or glutamate. In some embodiments, the acidic amino acid(s) is glutamate. In some embodiments, the non-acidic amino acid(s) is glycine, proline, or serine. In some embodiments, the non-acidic amino acid(s) is glycine.
[0010] In some embodiments, the linker peptide comprises one or more of the amino acid sequences of SEQ ID NOs: 14, 15, 16, 17, or 18. In some embodiments, the linker peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 19-23.
[0011] In some embodiments, the first peptide comprises an amino acid sequence of DSWX3EEVIKLCGRELVRAQIAICGX4ST (SEQ ID NO: 3), where X3 is methionine, lysine, or glutamine, and X4 is methionine or lysine. In some embodiments, the first peptide comprises an amino acid sequence of X5QX6YSALANKCCHVGCTKRSLAX7FC (SEQ ID NO: 4), where X5 is arginine or absent, X6 is leucine or aspartic acid, and X7 is arginine, glutamine, or glutamate.
[0012] In some embodiments, the second peptide comprises the amino acid sequence of DSWX3EEVIKLCGRELVRAQIAICGX4ST (SEQ ID NO: 3), where X3 is methionine, lysine, or glutamine, and X4 is methionine or lysine. In some embodiments, the second peptide comprises the amino acid sequence of X5QX6YSALANKCCHVGCTKRSLAX7FC (SEQ ID NO: 4), where X5 is arginine or absent, X6 is leucine or aspartate, and X7 is arginine, glutamine, or glutamate.
[0013] In some embodiments, the first peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-7. In some embodiments, the second peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-7. In some embodiments, the first peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-13. In some embodiments, the second peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-13.
[0014] In some embodiments, a first peptide comprises the amino acid sequence of SEQ ID NO:5 and a second peptide comprises the amino acid sequence of SEQ ID NO:8, or a first peptide comprises the amino acid sequence of SEQ ID NO:5 and a second peptide comprises the amino acid sequence of SEQ ID NO:9, or a first peptide comprises the amino acid sequence of SEQ ID NO:5 and a second peptide comprises the amino acid sequence of SEQ ID NO:10, or a first peptide comprises the amino acid sequence of SEQ ID NO:5 and a second peptide comprises the amino acid sequence of SEQ ID NO:11, or a first peptide comprises the amino acid sequence of SEQ ID NO:5 and a second peptide comprises the amino acid sequence of SEQ ID NO: or the first peptide comprises the amino acid sequence of SEQ ID NO: 5 and the second peptide comprises the amino acid sequence of SEQ ID NO: 13; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 8; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 9; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 10. or a first peptide comprises the amino acid sequence of SEQ ID NO:6 and a second peptide comprises the amino acid sequence of SEQ ID NO:11; or a first peptide comprises the amino acid sequence of SEQ ID NO:6 and a second peptide comprises the amino acid sequence of SEQ ID NO:12; or a first peptide comprises the amino acid sequence of SEQ ID NO:6 and a second peptide comprises the amino acid sequence of SEQ ID NO:13; or a first peptide comprises the amino acid sequence of SEQ ID NO:7 and a second peptide comprises the amino acid sequence of SEQ ID NO:8; or a first peptide comprises the amino acid sequence of SEQ ID NO:7. , wherein the second peptide comprises the amino acid sequence of SEQ ID NO:9; or wherein the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:10; or wherein the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:11; or wherein the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:12; or wherein the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:13.
[0015] In some embodiments, the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:8, or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:9, or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:10, or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:11, or the second peptide comprises the amino acid sequence of SEQ ID NO:5. or the second peptide comprises the amino acid sequence of SEQ ID NO: 6, and the first peptide comprises the amino acid sequence of SEQ ID NO: 8, or the second peptide comprises the amino acid sequence of SEQ ID NO: 6, and the first peptide comprises the amino acid sequence of SEQ ID NO: 9, or the second peptide comprises the amino acid sequence of SEQ ID NO: 6, and the first peptide comprises the amino acid sequence of SEQ ID NO: 10. or the second peptide comprises the amino acid sequence of SEQ ID NO:6, and the first peptide comprises the amino acid sequence of SEQ ID NO:11, or the second peptide comprises the amino acid sequence of SEQ ID NO:6, and the first peptide comprises the amino acid sequence of SEQ ID NO:12, or the second peptide comprises the amino acid sequence of SEQ ID NO:6, and the first peptide comprises the amino acid sequence of SEQ ID NO:13, or the second peptide comprises the amino acid sequence of SEQ ID NO:7, and the first peptide comprises the amino acid sequence of SEQ ID NO:8, or the second peptide comprises the amino acid sequence of SEQ ID NO:7. , the first peptide comprises the amino acid sequence of SEQ ID NO:9, or the second peptide comprises the amino acid sequence of SEQ ID NO:7, or the first peptide comprises the amino acid sequence of SEQ ID NO:10, or the second peptide comprises the amino acid sequence of SEQ ID NO:7, and the first peptide comprises the amino acid sequence of SEQ ID NO:11, or the second peptide comprises the amino acid sequence of SEQ ID NO:7, and the first peptide comprises the amino acid sequence of SEQ ID NO:12, or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:13.
[0016] In some embodiments, the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:25-48.
[0017] In some embodiments, the first peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-7. In some embodiments, the second peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-7. In some embodiments, the first peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-13. In some embodiments, the second peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-13.
[0018] In some embodiments, the first peptide consists of the amino acid sequence of SEQ ID NO:5 and the second peptide consists of the amino acid sequence of SEQ ID NO:8; or the first peptide consists of the amino acid sequence of SEQ ID NO:5 and the second peptide consists of the amino acid sequence of SEQ ID NO:9; or the first peptide consists of the amino acid sequence of SEQ ID NO:5 and the second peptide consists of the amino acid sequence of SEQ ID NO:10; or the first peptide consists of the amino acid sequence of SEQ ID NO:5 and the second peptide consists of the amino acid sequence of SEQ ID NO:11; or the first peptide consists of the amino acid sequence of SEQ ID NO:5 and the second peptide consists of the amino acid sequence of SEQ ID NO: or the first peptide comprises the amino acid sequence of SEQ ID NO: 5 and the second peptide comprises the amino acid sequence of SEQ ID NO: 13; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 8; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 9; or the first peptide comprises the amino acid sequence of SEQ ID NO: 6 and the second peptide comprises the amino acid sequence of SEQ ID NO: 10. or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:11, or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:12, or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:13, or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:8, or the first peptide comprises the amino acid sequence of SEQ ID NO:7. , the second peptide consists of the amino acid sequence of SEQ ID NO:9, or the first peptide consists of the amino acid sequence of SEQ ID NO:7 and the second peptide consists of the amino acid sequence of SEQ ID NO:10, or the first peptide consists of the amino acid sequence of SEQ ID NO:7 and the second peptide consists of the amino acid sequence of SEQ ID NO:11, or the first peptide consists of the amino acid sequence of SEQ ID NO:7 and the second peptide consists of the amino acid sequence of SEQ ID NO:12, or the first peptide consists of the amino acid sequence of SEQ ID NO:7 and the second peptide consists of the amino acid sequence of SEQ ID NO:13.
[0019] In some embodiments, the second peptide consists of the amino acid sequence of SEQ ID NO:5 and the first peptide consists of the amino acid sequence of SEQ ID NO:8; or the second peptide consists of the amino acid sequence of SEQ ID NO:5 and the first peptide consists of the amino acid sequence of SEQ ID NO:9; or the second peptide consists of the amino acid sequence of SEQ ID NO:5 and the first peptide consists of the amino acid sequence of SEQ ID NO:10; or the second peptide consists of the amino acid sequence of SEQ ID NO:5 and the first peptide consists of the amino acid sequence of SEQ ID NO:11; or the second peptide consists of the amino acid sequence of SEQ ID NO:5. or the second peptide comprises the amino acid sequence of SEQ ID NO: 6 and the first peptide comprises the amino acid sequence of SEQ ID NO: 8; or the second peptide comprises the amino acid sequence of SEQ ID NO: 6 and the first peptide comprises the amino acid sequence of SEQ ID NO: 9; or the second peptide comprises the amino acid sequence of SEQ ID NO: 6 and the first peptide comprises the amino acid sequence of SEQ ID NO: 10; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:11, or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:12, or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:13, or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:8, or the second peptide comprises the amino acid sequence of SEQ ID NO:7. , the first peptide consists of the amino acid sequence of SEQ ID NO:9, or the second peptide consists of the amino acid sequence of SEQ ID NO:7, and the first peptide consists of the amino acid sequence of SEQ ID NO:10, or the second peptide consists of the amino acid sequence of SEQ ID NO:7 and the first peptide consists of the amino acid sequence of SEQ ID NO:11, or the second peptide consists of the amino acid sequence of SEQ ID NO:7 and the first peptide consists of the amino acid sequence of SEQ ID NO:12, or the second peptide consists of the amino acid sequence of SEQ ID NO:7 and the first peptide consists of the amino acid sequence of SEQ ID NO:13.
[0020] In some embodiments, the fusion protein further comprises an IgG Fc. In some embodiments, the IgG Fc comprises the amino acid alanine at EU positions 234 and 235. In some embodiments, the IgG Fc comprises the amino acid alanine at EU position 329. In some embodiments, the IgG Fc comprises the amino acid alanine at EU positions 234, 235 and 329. In some embodiments, the IgG Fc comprises the amino acids alanine, alanine, alanine, leucine and serine at EU positions 234, 235, 329, 428 and 434, respectively. In some embodiments, the IgG Fc comprises the amino acids lysine, phenylalanine and tyrosine at EU positions 433, 434 and 436, respectively. In some embodiments, the IgG Fc comprises the amino acids tyrosine, threonine and glutamate at EU positions 252, 254 and 256, respectively. In some embodiments, the IgG Fc comprises the amino acids leucine and serine at EU positions 428 and 434, respectively.
[0021] In some embodiments, IgG Fc comprises an amino acid sequence at least 85% identical to the amino acid sequence of human IgG1 Fc. In some embodiments, IgG Fc comprises the amino acid sequence of human IgG1 Fc. In some embodiments, IgG Fc comprises an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-52 and 201-203. In some embodiments, IgG Fc comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-52 and 201-203.
[0022] In some embodiments, the IgG Fc is linked to the N-terminus of the first peptide. In some embodiments, the IgG Fc is linked to the C-terminus of the second peptide.
[0023] In some embodiments, the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-85 and 204-211. In some embodiments, the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 86-118 and 214-221.
[0024] In some embodiments, the fusion protein consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-85 and 204-211. In some embodiments, the fusion protein consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 86-118 and 214-221.
[0025] In some embodiments, the first and second peptides are DSWKEEVIKLCGRELVRAQIAICGKSTAS (SEQ ID NO: 187), DSWKEEVIKLCGRELVRAQIAICGKSTWS (SEQ ID NO: 188), DSWMEEVIKLCGRELVRAQIAICGKSTAS (SEQ ID NO: 189), and does not contain the amino acid sequence of a peptide selected from the group consisting of: DSWMEEVIKLCGRELVRAQIAICGKSTWS (SEQ ID NO: 190).
[0026] Also provided herein is a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 53 to 118 and 204 to 225. In some embodiments, the fusion protein consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 53 to 118 and 204 to 225.
[0027] Also provided herein is a polynucleotide comprising a nucleotide sequence encoding any of the fusion proteins described above and provided herein. In some embodiments, the polynucleotide is an RNA molecule. In some embodiments, the polynucleotide is a DNA molecule.
[0028] Also provided herein is an expression vector comprising any of the polynucleotides described above and herein. In some embodiments, the expression vector is a plasmid. In some embodiments, the expression vector is a viral vector.
[0029] Also provided herein is a host cell comprising any of the polynucleotides or expression vectors described above and herein. In some embodiments, the host cell is a prokaryotic cell. In some embodiments, the host cell is a eukaryotic cell. In some embodiments, the prokaryotic cell is an E. coli cell or a Bacillus cell. In some embodiments, the eukaryotic cell is selected from the group consisting of a yeast cell, an insect cell, and a mammalian cell. In some embodiments, the mammalian cell is selected from the group consisting of a CHO cell, a HeLa cell, and a 293 cell.
[0030] Also provided herein is a population of cells comprising two or more of any of the host cells described above and herein.
[0031] Also provided herein is a method of producing any of the fusion proteins described above and herein, comprising culturing any of the host cells described above and herein under conditions such that the fusion protein is produced.
[0032] Also provided herein is a pharmaceutical composition comprising an effective amount of any of the fusion proteins described above and herein, or any of the polynucleotides described above and herein, or any of the expression vectors described above and herein.
[0033] Also provided herein is a method of enhancing relaxin-2-related activity in a primary cell, comprising contacting the primary cell with any of the fusion proteins described above and herein, thereby enhancing relaxin-2-related activity in the cell. In some embodiments, the fusion protein activates the relaxin-2 receptor, RXFP1, on the cell surface. In some embodiments, the method increases cAMP levels in the primary cell, induces vasodilation, induces expression of angiogenic factors, induces expression of MMPs, and induces collagen degradation. In some embodiments, the primary cell is selected from the group consisting of endothelial cells, vascular smooth muscle cells, other vascular cells, cardiomyocytes, other cardiac cells, and fibroblasts. In some embodiments, the primary cell is in a subject. In some embodiments, the subject has a relaxin-2-related disorder. In some embodiments, the relaxin-2-related disorder is selected from the group consisting of renal disease, fibrotic disease, and cardiovascular disease. In some embodiments, the disorder is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, hepatorenal syndrome, scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cardiac fibrosis, NASH, dilated cardiomyopathy, diastolic heart failure, pulmonary arterial hypertension, chronic heart failure, acute heart failure, congestive heart failure, coronary artery disease, hypertension, and pre-eclampsia.
[0034] Also provided herein is a method of treating a relaxin-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of any of the fusion proteins described above and herein, any of the polynucleotides described above and herein, any of the expression vectors described above and herein, or any of the pharmaceutical compositions described above and herein, thereby treating the relaxin-related disorder. In some embodiments, the relaxin-2-related disorder is selected from the group consisting of renal disease, fibrotic disease, and cardiovascular disease. In some embodiments, the disorder is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, hepatorenal syndrome, scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cardiac fibrosis, NASH, dilated cardiomyopathy, diastolic heart failure, pulmonary arterial hypertension, chronic heart failure, acute heart failure, congestive heart failure, coronary artery disease, hypertension, and pre-eclampsia. In some embodiments, the method reduces arterial pressure, increases renal artery blood flow, increases cardiac filling during diastole, resolves established fibrosis, or inhibits the development of new fibrosis.
[0035] Also provided herein is a kit comprising an effective amount of any of the fusion proteins described above and herein, any of the polynucleotides described above and herein, any of the expression vectors described above and herein, or any of the pharmaceutical compositions described above and herein, and instructions for use. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0036] The present disclosure provides a fusion protein comprising a human relaxin-2B chain, or a derivative thereof, and a human relaxin-2A chain, or a derivative thereof, linked by a peptide linker, the fusion protein having a high in vivo circulatory half-life when administered to a mammal. In some embodiments, the in vivo circulatory half-life of the fusion protein provided herein is greater than 2 hours. In some embodiments, the fusion protein provided herein has a low pI. In some embodiments, the pI of the fusion protein provided herein is less than 8.5. In some embodiments, the low pI of the fusion protein provided herein is caused by acidic amino acid residues present in the peptide linker. In some embodiments, the peptide linker of the fusion protein comprises two or more acidic amino acids. In some embodiments, the peptide linker is 10-15 amino acids in total length.
[0037] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are merely exemplary and explanatory and are not intended to limit any claimed subject matter. In this application, the use of the singular includes the plural unless otherwise noted. It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the term "including," as well as other forms of "include," "includes," and "included," are not limiting. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0038] The term "polynucleotide" as used herein refers to a polymer of DNA or RNA. Polynucleotide sequences may be single-stranded or double-stranded, may contain natural, non-natural, or modified nucleotides, and may contain natural, non-natural, or modified internucleotide bonds, such as phosphoramidate or phosphorothioate bonds, instead of the phosphodiesters found between nucleotides in unmodified polynucleotide sequences. Polynucleotide sequences include, but are not limited to, all polynucleotide sequences obtained by any means available in the art, including, but not limited to, recombinant means, such as cloning polynucleotide sequences from recombinant libraries or cell genomes, using conventional cloning techniques and the polymerase chain reaction, and synthetic means.
[0039] The terms "amino acid sequence" and "polypeptide" are used interchangeably herein and refer to a polymer of amino acids joined by one or more peptide bonds. As used herein, "amino acid sequence" refers to information that describes the relative order and identity of the amino acid residues that make up a polypeptide.
[0040] As used herein, with reference to an amino acid sequence, the term "amino acid sequence that differs in one or more amino acids" refers to an amino acid sequence that contains at least one substitution, modification, inversion, addition, or deletion of an amino acid residue compared to a reference amino acid sequence.
[0041] The determination of "percent identity" between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. A specific, non-limiting example of a mathematical algorithm utilized for comparing two sequences is the algorithm of Karlin S & Altschul SF, (1990) PNAS 87:2264-2268, modified as in Karlin S & Altschul SF, (1993) PNAS 90:5873-5877, each of which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul SF et al., (1990) J Mol Biol 215:403, which are incorporated herein by reference in their entirety. BLAST nucleotide searches can be performed, for example, with the NBLAST nucleotide program parameters set to score=100, word length=12, etc., to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. To obtain amino acid sequences homologous to the protein molecules described herein, BLAST protein searches can be performed using the XBLAST program parameters set, for example, score 50, word length = 3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul SF et al., (1997) Nuc Acids Res 25:3389-3402, the entirety of which is incorporated herein by reference. Alternatively, PSI BLAST can be used to perform an iterative search that detects distant relationships between molecules. When utilizing Id.BLAST, Gapped BLAST, and PSI BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, for example, National Center for Biotechnology Information (NCBI) on the worldwide web, ncbi.nlm.nih.gov).Another specific, non-limiting example of a mathematical algorithm utilized for comparing sequences is the algorithm of Myers and Miller, (1988), CABIOS 4:11-17, which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0042] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating the percent identity, typically only exact matches are counted.
[0043] As used herein, the term "linked to" refers to a covalent or non-covalent bond between two molecules or moieties. One of skill in the art will understand that when a first molecule or moiety is linked to a second molecule or moiety, the linkage need not be direct, but may instead be through an intervening molecule or moiety.
[0044] As used herein, the term "human relaxin-2 B chain" or "relaxin B chain" or "relaxin B" or "relB" refers to a peptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a derivative thereof. In some embodiments, a derivative of relaxin B chain comprises the amino acid sequence of SEQ ID NO: 1 with 1, 2, 3, 4, or 5 amino acid changes.
[0045] As used herein, the term "human relaxin-2A chain" or "relaxin A chain" or "relaxin A" or "rel A" refers to a peptide comprising or consisting of the amino acid sequence set forth in QLYSALANKCCHVGCTKRSLARFC (SEQ ID NO: 2), or a derivative thereof. In some embodiments, a derivative of relaxin A chain comprises the amino acid sequence of SEQ ID NO: 2 with 1, 2, 3, 4, or 5 amino acid changes.
[0046] As used herein, the term "linker peptide" refers to a peptide that links the relaxin A chain and the relaxin B chain in the fusion proteins described herein.
[0047] As used herein, the term "acidic amino acid" refers to an amino acid having a carboxylic acid in its side chain. In some embodiments, the acidic amino acid is aspartate, glutamate, 2-aminoadipic acid, 2-aminobutyric acid, or 2-aminopimelic acid. In some embodiments, the acidic amino acid includes aspartate and glutamate.
[0048] As used herein, the term "non-acidic amino acid" refers to an amino acid that is not an acidic amino acid. In some embodiments, non-acidic amino acids include glycine, proline, and serine. In some embodiments, non-specific amino acids also include arginine, histidine, lysine, threonine, asparagine, glutamine, cysteine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan.
[0049] As used herein, the term "IgG Fc" refers to the crystallizable (Fc) region of an immunoglobulin G (IgG) fragment. In some embodiments, the IgG Fc is a human IgG1, IgG2, IgG3, or IgG4 Fc region. In some embodiments, the IgG Fc is an IgG1 Fc region.
[0050] As used herein, the term "EU numbering system" refers to the EU numbering rules for antibody constant regions as described in Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969) and Kabat et al., Sequences of Proteins of Immunological Interest, USDept. Health and Human Services, 5th edition, 1991, each of which is incorporated herein by reference in its entirety.
[0051] As used herein, the term "relaxin-2 receptor," "human relaxin-2 receptor," "human relaxin receptor 1," "RXFP1," or "LGR7" refers to the native receptor for relaxin-2 in humans. In some embodiments, RXFP1 comprises the amino acid sequence set forth in the NCBI reference sequences: NP_067647.2, NP_001240656.1, NP_001240657.1, NP_001240658.1, NP_001240659.1, NP_001240661.1, NP_001240662.1, or NP_001350705.1, which are incorporated by reference herein in their entireties.
[0052] As used herein, the terms "treat", "treating" and "treatment" refer to therapeutic or prophylactic measures as described herein. In some embodiments, the method of "treatment" employs administering a fusion protein to a subject having or previously diagnosed with a disease or disorder to prevent, cure, delay, reduce the severity of, or ameliorate a disease or disorder, or one or more symptoms of a recurrent disease or disorder, or to extend the subject's survival beyond that expected in the absence of such treatment.
[0053] As used herein, in the context of administering a therapy, the term "effective amount" refers to the amount of the therapy that achieves a desired prophylactic or therapeutic effect.
[0054] As used herein, the term "subject" includes any human or non-human animal. In one embodiment, the subject is a human or non-human mammal. In one embodiment, the subject is a human.
[0055] As used herein, the term "pI" refers to the isoelectric point, i.e., the pH of a solution at which the next charge on the fusion protein is zero. In some embodiments, the pI is a calculated pI or a theoretical pI. In some embodiments, the pI is experimentally measured by an instrument.
[0056] Fusion proteins The present disclosure provides a fusion protein comprising human relaxin-2B chain, or a derivative thereof, and human relaxin-2A chain, or a derivative thereof, linked by a peptide linker, wherein the fusion protein has a high in vivo circulatory half-life when administered to a mammal. In some embodiments, the fusion protein comprises, from N-terminus to C-terminus, human relaxin-2B chain, or a derivative thereof, a peptide linker, and human relaxin-2A chain, or a derivative thereof. In some embodiments, the fusion protein comprises, from N-terminus to C-terminus, human relaxin-2A chain, or a derivative thereof, a peptide linker, and human relaxin-2B chain, or a derivative thereof. In some embodiments, the fusion protein further comprises an IgG Fc. The IgG Fc is linked to the N-terminus or C-terminus of the human relaxin B chain linker protein-human relaxin A chain fusion protein or the human relaxin A chain linker protein-human relaxin B chain fusion protein. In some embodiments, the IgG Fc is replaced with PEG.
[0057] Human relaxin-2 B chain derivative The present disclosure provides human relaxin-2 B chain derivatives, which have 1, 2, 3, 4, or 5 amino acid changes compared to the amino acid sequence of SEQ ID NO:1. In some embodiments, the amino acid corresponding to position 13 of SEQ ID NO:1 must be an arginine. In some embodiments, the amino acid corresponding to position 17 of SEQ ID NO:1 must be an arginine. In some embodiments, the amino acid corresponding to position 20 of SEQ ID NO:1 must be an isoleucine. In some embodiments, the amino acid corresponding to position 13 of SEQ ID NO:1 must be an arginine, the amino acid corresponding to position 17 of SEQ ID NO:1 must be an arginine, and the amino acid corresponding to position 20 of SEQ ID NO:1 must be an isoleucine.
[0058] In some embodiments, the human relaxin-2 B chain derivative comprises or consists of the following formula: DSWX3EEVIKLCGRELVRAQIAICGX4ST (SEQ ID NO: 3), where X3 and X4 are absent or any amino acid. In some embodiments, X3 is methionine, lysine, or glutamine, and X4 is methionine or lysine. In some embodiments, X4 is lysine.
[0059] In some embodiments, the human relaxin-2 B chain derivative used in the fusion proteins described herein does not comprise the amino acid sequence of SEQ ID NOs: 187-190.
[0060] In some embodiments, the human relaxin-2B chain derivative is 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 amino acids in length. In some embodiments, the human relaxin-2B chain derivative is 25, 26, 27, 28, or 29 amino acids in length. In some embodiments, the human relaxin-2B chain derivative is 27 amino acids in length.
[0061] In some embodiments, the human relaxin-2 B chain derivative comprises or consists of the amino acid sequence shown in Table 1 below. [Table 1]
[0062] Human relaxin-2 A chain derivative The present disclosure provides human relaxin-2 A chain derivatives, which have 1, 2, 3, 4, or 5 amino acid changes compared to the amino acid sequence of SEQ ID NO:2. In some embodiments, the amino acid corresponding to position 3 of SEQ ID NO:2 must be lysine. In some embodiments, the amino acid corresponding to position 23 of SEQ ID NO:2 must be phenylalanine. In some embodiments, the amino acid corresponding to position 3 of SEQ ID NO:2 must be lysine and the amino acid corresponding to position 23 of SEQ ID NO:2 must be phenylalanine.
[0063] In some embodiments, the human relaxin-2 A chain derivative comprises or consists of the formula: X5QX6YSALANKCCHVGCTKRSLAX7FC (SEQ ID NO: 4), where X5, X6, and X7 are absent or any amino acid. In some embodiments, X5 is arginine or absent, X6 is leucine or aspartate, and X7 is arginine, glutamine, or glutamate.
[0064] In some embodiments, the human relaxin-2A chain derivative is 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids in length. In some embodiments, the human relaxin-2A chain derivative is 22, 23, 24, 25, or 26 amino acids in length. In some embodiments, the human relaxin-2A chain derivative is 24 amino acids in length. In some embodiments, the human relaxin-2A chain derivative is 25 amino acids in length.
[0065] In some embodiments, the human relaxin-2 A chain derivative comprises or consists of the amino acid sequence shown in Table 2 below. [Table 2]
[0066] Linker Peptide The present disclosure provides a linker peptide, the peptide having at least two acidic amino acids. In some embodiments, the acidic amino acid is glutamate. In some embodiments, the acidic amino acid is aspartate. In some embodiments, the acidic amino acid is a non-standard amino acid. In some embodiments, the acidic amino acid is 2-aminoadipic acid, 2-aminobutyric acid, or 2-aminopimelic acid. In some embodiments, the linker peptide has 2, 3, 4, 5, 6, 7, 8, 9, or 10 acidic amino acids.
[0067] In some embodiments, the linker peptide is 8, 9, 10, 11, 12, 13, 14, or 15 amino acids long. In some embodiments, the linker peptide is 12, 13, 14, or 15 amino acids long. In some embodiments, the linker peptide has 2, 3, 4, or 5 acidic amino acids. In some embodiments, the linker peptide is 12, 13, 14, or 15 amino acids long and has 2, 3, 4, or 5 acidic amino acids. In some embodiments, the remaining amino acids are non-acidic amino acids. In some embodiments, the non-acidic amino acids can be any standard amino acid that is not aspartate or glutamate. In some embodiments, the non-acidic amino acid can be any amino acid that does not have a carboxylic acid in its side chain. In some embodiments, the non-acidic amino acid is glycine, proline, serine, arginine, histidine, lysine, threonine, asparagine, glutamine, cysteine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, or tryptophan. In some embodiments, the non-acidic amino acid is glycine, proline, or cysteine, hi some embodiments, the non-acidic amino acid is glycine.
[0068] In some embodiments, the linker peptide comprises acidic amino acids, and all of the acidic amino acids are the same amino acid. In some embodiments, the acidic amino acids in the linker peptide are both / all glutamate. In some embodiments, the acidic amino acids in the linker peptide are both / all aspartate. In some embodiments, the linker peptide comprises amino acids that are a mixture of acidic amino acids. In some embodiments, the linker peptide comprises both glutamate and aspartate as acidic amino acids.
[0069] In some embodiments, the linker peptide is R1R1R1R2R1R1R1R2R1R1R1R2R1 (SEQ ID NO: 195), R1R1R1R2R1R1R1R2R1R1R1R2R1R1R1 (SEQ ID NO: 196), R1R1R2R1R1R2R2R1R1R1R2R1R1R2R1R1 (SEQ ID NO: 197), R1R1R1R2R2R1R1R1R2R2R1R1R1 (SEQ ID NO: 198), and R1R1R2R1R2R1R1R2R1R2R1R1R1 (SEQ ID NO: 199), R1 is a non-acidic amino acid and R2 is an acidic amino acid.
[0070] In some embodiments, the linker peptide comprises non-acidic amino acids, and all of the non-acidic amino acids are the same amino acid. In some embodiments, all of the non-acidic amino acids in the linker peptide are glycine. In some embodiments, the linker peptide comprises amino acids that are a mixture of non-acidic amino acids. In some embodiments, the linker peptide comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 different types of non-acidic amino acids.
[0071] In some embodiments, the linker peptide comprises or consists of an amino acid sequence shown in Table 3 below. [Table 3]
[0072] In some embodiments, the linker peptide comprises 2, 3, 4, or 5 repeats of SEQ ID NO: 14, 15, 16, 17, or 18. For example, three repeats of SEQ ID NO: 14 are the amino acid sequence GGGEGGGEGGGE (SEQ ID NO: 24).
[0073] Relaxin / Linker Peptide Combinations for Fusion Proteins In some embodiments, the fusion protein comprises an N-terminal or first peptide, a linker peptide, and a C-terminal or second peptide. In some embodiments, the N-terminal peptide comprises a human relaxin-2A chain or a derivative thereof, and the C-terminal peptide comprises a human relaxin-2B chain or a derivative thereof. In some embodiments, the N-terminal peptide comprises a human relaxin-2B chain or a derivative thereof, and the C-terminal peptide comprises a human relaxin-2A chain or a derivative thereof. Any combination of any of the embodiments of the human relaxin-2A chain or a derivative thereof and the human relaxin-2A chain or a derivative thereof linked by any of the linker peptides disclosed herein can be used to construct the embodiments of the fusion protein described herein. In some embodiments, at least one of the N-terminal peptide and the C-terminal peptide is a derivative of the human relaxin-2A chain or the human relaxin-2B chain. In some embodiments, the N-terminal peptide comprises a human relaxin-2A chain derivative, and the C-terminal peptide comprises a human relaxin-2B chain derivative. In some embodiments, the N-terminal peptide comprises a human relaxin-2 B chain derivative and the C-terminal peptide comprises a human relaxin-2 A chain derivative. Specific embodiments of the fusion proteins provided in this disclosure are shown in Table 4 below. [Table 4] [Table 5-1] [Table 5-2] [Table 6] [Table 7-1] [Table 7-2] [Table 8]
[0074] In some embodiments, there are additional amino acids between the N-terminal peptide and the linker peptide. In some embodiments, there are additional amino acids between the C-terminal peptide and the linker peptide. In some embodiments, there are no additional amino acids between the N-terminal peptide and the linker peptide. In some embodiments, there are no additional amino acids between the C-terminal peptide and the linker peptide.
[0075] In some embodiments, the portion of the fusion protein comprising the N-terminal peptide, the linker peptide, and the C-terminal peptide comprises or consists of the amino acid sequence shown in Table 5 below. [Table 9-1] [Table 9-2]
[0076] IgG Fc In some embodiments, the fusion proteins provided herein further comprise an IgG Fc. The IgG Fc can be linked to the N-terminus of the N-terminal peptide or the C-terminus of the C-terminal peptide. The IgG Fc can be linked directly to the N-terminus or C-terminus peptide, or they can be linked to the N-terminus or C-terminus peptide via an IgG Fc linker. In some embodiments, the IgG Fc linker comprises or consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid sequences. In some embodiments, the IgG Fc linker comprises or consists of 1, 2, 3, 4, or 5 amino acids. In some embodiments, the IgG Fc linker comprises or consists of 3 or 4 amino acids. In some embodiments, the IgG Fc linker comprises or consists of the amino acid sequence of GGS (SEQ ID NO: 193). It is known in the art that the C-terminal lysine (K) in many monoclonal antibodies is flexible and is often cleaved during expression and purification with no known impediment to activity. In some embodiments, the IgG Fc comprises an amino acid sequence of one of SEQ ID NOs: 49-52 together with SEQ ID NO: 193 as an IgG Fc linker at the C-terminus of the IgG Fc. In some embodiments, the IgG Fc comprises an amino acid sequence of one of SEQ ID NOs: 200-203 together with SEQ ID NO: 193 as an IgG Fc linker at the C-terminus of the IgG Fc.
[0077] In some embodiments, one, two, or more mutations (e.g., amino acid substitutions) are introduced in the Fc region (e.g., the CH2 domain (residues 231-340 of human IgG1) and / or the CH3 domain (residues 341-447 of human IgG1)) and / or hinge region of an antibody described herein, numbered according to the EU numbering system, to alter one or more functional properties of the antibody, e.g., serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cellular cytotoxicity.
[0078] In certain embodiments, one, two, or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region is altered (e.g., increased or decreased), e.g., as described in U.S. Patent No. 5,677,425, which is incorporated herein by reference in its entirety. The number of cysteine residues in the hinge region of the CH1 domain can be altered, for example, to facilitate assembly of the light and heavy chains or to alter (e.g., increase or decrease) the stability of the antibody.
[0079] In a specific embodiment, one, two or more amino acid mutations (e.g., substitutions, insertions or deletions) are introduced into an IgG constant domain, or an FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment), to modify (e.g., decrease or increase) the half-life of the antibody in vivo. For examples of mutations that modify (e.g., decrease or increase) the half-life of an antibody in vivo, see, for example, International Publication Nos. WO02 / 060919, WO98 / 23289, and WO97 / 34631, as well as U.S. Patent Nos. 5,869,046, 6,121,022, 6,277,375, and 6,165,745, all of which are incorporated herein by reference in their entirety. In certain embodiments, one, two, or more amino acid mutations (e.g., substitutions, insertions, or deletions) are introduced into an IgG constant domain, or an FcRn-binding fragment thereof (preferably, an Fc or hinge-Fc domain fragment) to decrease the half-life of the antibody in vivo. In other embodiments, one, two, or more amino acid mutations (e.g., substitutions, insertions, or deletions) are introduced into an IgG constant domain, or an FcRn-binding fragment thereof (preferably, an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody in vivo. In specific embodiments, the antibody may have one or more amino acid mutations (e.g., substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and / or the third constant (CH3) domain (residues 341-447 of human IgG1), numbered according to the EU numbering system. In a specific embodiment, the IgG1 constant region of the antibody described herein comprises a methionine (M) to tyrosine (Y) substitution at position 252, a serine (S) to threonine (T) substitution at position 254, and a threonine (T) to glutamic acid (E) substitution at position 256, numbered according to the EU numbering system. See U.S. Patent No. 7,658,921, which is incorporated herein by reference in its entirety.Mutant IgGs of this type, termed "YTE mutants," have been shown to exhibit a four-fold increased half-life compared to the wild-type version of the same antibody (see Dall'Acqua WF et al., (2006) J Biol Chem 281:23514-24, which is incorporated herein by reference in its entirety). In certain embodiments, the antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions at amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU numbering system.
[0080] In certain embodiments, one, two, or more mutations (e.g., amino acid substitutions) are introduced into the Fc region (e.g., the CH2 domain (residues 231-340 of human IgG1) and / or the CH3 domain (residues 341-447 of human IgG1)) and / or hinge region of an antibody described herein, numbered according to the EU numbering system, to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activating Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of the antibody for an Fc receptor, and techniques for introducing such mutations into an Fc receptor or a fragment thereof, are known to those of skill in the art. Examples of mutations in the Fc receptors of antibodies that can be made to alter the affinity of the antibody for the Fc receptor are described, for example, in Smith P et al., (2012) PNAS 109:6181-6186, U.S. Patent No. 6,737,056, and International Publication Nos. WO02 / 060919, WO98 / 23289, and WO97 / 34631, all of which are incorporated by reference herein in their entireties.
[0081] In certain embodiments, the antibody comprises a heavy chain constant region that is a variant of the wild-type heavy chain constant region, and the variant heavy chain constant region binds to FcγRIIB with a higher affinity than the wild-type heavy chain constant region binds to FcγRIIB. In certain embodiments, the variant heavy chain constant region is a variant human heavy chain constant region, such as a variant human IgG1, variant human IgG2, or variant human IgG4 heavy chain constant region. In certain embodiments, the variant human IgG heavy chain constant region comprises one or more of the following amino acid mutations according to the EU numbering system: G236D, P238D, S239D, S267E, L328F, and L328E. In certain embodiments, the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of S267E and L328F, P238D and L328E, P238D, and one or more substitutions selected from the group consisting of E233D, G237D, H268D, P271G, and A330R, P238D, E233D, G237D, H268D, P271G, and A330R, G236D and S267E, S239D and S267E, V262E, S267E, and L328F, and V264E, S267E, and L328F, numbered according to the EU numbering system. In certain embodiments, FcγRIIB is expressed on a cell selected from the group consisting of a macrophage, a monocyte, a B cell, a dendritic cell, an endothelial cell, and an activated T cell.
[0082] In further embodiments, one, two or more amino acid substitutions are introduced into the IgG constant domain Fc region to modify the effector function(s) of the antibody. For example, one or more amino acids selected from amino acid residues 234, 235, 236, 237, 239, 243, 267, 292, 297, 300, 318, 320, 322, 328, 330, 332, and 396, numbered according to the EU numbering system, can be replaced with different amino acid residues such that the antibody has an altered affinity for an effector ligand, but retains the antigen-binding ability of the parent antibody. The affinity-altered effector ligand can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Patent Nos. 5,624,821 and 5,648,260, each of which is incorporated herein by reference in its entirety. In certain embodiments, deletion or inactivation of the constant region domain (by point mutation or other means) may reduce Fc receptor binding of circulating antibodies, thereby increasing tumor localization. For example, see U.S. Patent Nos. 5,585,097 and 8,591,886, each of which is incorporated herein by reference in its entirety, for a description of mutations that delete or inactivate constant domains, thereby increasing tumor localization. In certain embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on the Fc region, which may reduce Fc receptor binding (see, e.g., Shields RL et al., (2001) J Biol Chem 276:6591-604, which is incorporated herein by reference in its entirety).In various embodiments, one or more of the following mutations in the constant region of the antibodies described herein, numbered according to the EU numbering system, may be made: N297A substitution, N297Q substitution, L234A substitution, L234F substitution, L235A substitution, L235F substitution, L235V substitution, L237A substitution, S239D substitution, E233P substitution, L234V substitution, L235A substitution, C236 deletion, P238A substitution, S239D substitution, F243L substitution, D265A substitution, S267E substitution, L328F substitution, R292P substitution, Y300L substitution, A327Q substitution, P329A substitution (PA), A332L substitution, I332E substitution, or P396L substitution.
[0083] In certain embodiments, mutations selected from the group consisting of D265A, P329A, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of the antibody described herein. In certain embodiments, mutations selected from the group consisting of L235A, L237A, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of the antibody described herein. In certain embodiments, mutations selected from the group consisting of S267E, L328F, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of the antibody described herein. In certain embodiments, mutations selected from the group consisting of S239D, I332E, optionally A330L, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of the antibody described herein. In certain embodiments, a mutation selected from the group consisting of L235V, F243L, R292P, Y300L, P396L, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of an antibody described herein. In certain embodiments, a mutation selected from the group consisting of S267E, L328F, and combinations thereof, numbered according to the EU numbering system, may be made in the constant region of an antibody described herein.
[0084] In a specific embodiment, the antibody described herein comprises an IgG1 constant domain with an N297Q or N297A amino acid substitution, numbered according to the EU numbering system. In one embodiment, the antibody described herein comprises an IgG1 constant domain with a mutation selected from the group consisting of D265A, P329A, and combinations thereof, numbered according to the EU numbering system. In another embodiment, the antibody described herein comprises an IgG1 constant domain with a mutation selected from the group consisting of L234A, L235A (LALA), and combinations thereof, numbered according to the EU numbering system. In another embodiment, the antibody described herein comprises an IgG1 constant domain with a mutation selected from the group consisting of L234F, L235F, N297A, and combinations thereof, numbered according to the EU numbering system. In a specific embodiment, the amino acid residues in the constant region of the antibody described herein at positions corresponding to positions L234, L235, and D265 of the human IgG1 heavy chain, numbered according to the EU numbering system, are not L, L, and D, respectively. This approach is described in detail in International Publication No. WO14 / 108483, which is incorporated herein by reference in its entirety. In certain embodiments, the amino acids corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A, or A, A, and A, respectively, numbered according to the EU numbering system.
[0085] In certain embodiments, one or more amino acids selected from amino acid residues 329, 331, and 322 in the constant region of an antibody described herein, numbered according to the EU numbering system, can be replaced with a different amino acid residue such that the antibody has altered C1q binding and / or reduced or eliminated complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al.), which is incorporated herein by reference in its entirety. In certain embodiments, one or more amino acid residues within amino acid positions 231-238 in the N-terminal region of the CH2 domain of an antibody described herein, numbered according to the EU numbering system, are altered to thereby alter the antibody's ability to fix complement. This approach is described further in International Publication No. WO 94 / 29351, which is incorporated herein by reference in its entirety. In certain embodiments, the Fc region of an antibody described herein is selected from the following positions: 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 309, 312, 315, 320, 322, 324, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 365, 367, 368, 369, 370, 372, 376, 378, 380, 383, 385, 386, 389, 390, 392, 393, 394, 395, 396, 398, 301, 303, 305, 307, 309, 312, 315, The antibodies may be modified to increase their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or to increase their affinity for Fcγ receptors by mutating (e.g., introducing amino acid substitutions) one or more amino acids at 28, 329, 330, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438, or 439. This approach is further described in International Publication No. WO 00 / 42072, which is incorporated by reference in its entirety.
[0086] In some embodiments, the IgG Fc is an IgG1 Fc, or a derivative thereof. In some embodiments, the IgG Fc or IgG1 Fc comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, or 99% identical to the amino acid sequence of an IgG1 Fc. In some embodiments, the IgG Fc or IgG1 Fc comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, 99, or 100% identical to the amino acid sequence provided in Table 6 below. [Table 9-1] [Table 10-2]
[0087] In some embodiments, any IgG Fc, or derivative thereof, with or without an IgG Fc linker, may be linked to the N-terminus or C-terminus of any of the embodiments described in Tables 4 or 5 above. In some embodiments, human IgG1 Fc, or derivative thereof, with or without an IgG Fc linker, may be linked to the N-terminus or C-terminus of any of the embodiments described in Tables 4 or 5 above. In some embodiments, the amino acid sequence of human IgG1 Fc comprises or consists of the amino acid sequence of SEQ ID NO: 49 or 200. In some embodiments, a derivative of human IgG1 Fc comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, or 99% identical to the amino acid sequence of SEQ ID NO: 49 or 200.
[0088] In some embodiments, the human IgG1 Fc comprising the LALA mutation, or a derivative thereof, may be linked to the N-terminus or C-terminus of any of the embodiments described above in Tables 4 or 5, with or without an IgG Fc linker. In some embodiments, the amino acid sequence of the human IgG1 Fc comprising the LALA mutation comprises or consists of the amino acid sequence of SEQ ID NO: 50 or 201. In some embodiments, the derivative of the human IgG1 Fc comprising the LALA mutation comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, or 99% identical to the amino acid sequence of SEQ ID NO: 50 or 201.
[0089] In some embodiments, the human IgG1 Fc comprising the LALA PA mutation, or a derivative thereof, may be linked to the N-terminus or C-terminus of any of the embodiments described above in Tables 4 or 5, with or without an IgG Fc linker. In some embodiments, the amino acid sequence of the human IgG1 Fc comprising the LALA PA mutation comprises or consists of the amino acid sequence of SEQ ID NO: 51 or 202. In some embodiments, the derivative of the human IgG1 Fc comprising the LALA PA mutation comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, or 99% identical to the amino acid sequence of SEQ ID NO: 51 or 202.
[0090] In some embodiments, the human IgG1 Fc comprising the LALA PA LS mutation, or a derivative thereof, may be linked to the N-terminus or C-terminus of any of the embodiments described above in Tables 4 or 5, with or without an IgG Fc linker. In some embodiments, the amino acid sequence of the human IgG1 Fc comprising the LALA PA LS mutation comprises or consists of the amino acid sequence of SEQ ID NO: 52 or 203. In some embodiments, the derivative of the human IgG1 Fc comprising the LALA PA LS mutation comprises an amino acid sequence that is at least 85, 90, 95, 96, 97, 98, or 99% identical to the amino acid sequence of SEQ ID NO: 52 or 203.
[0091] In some embodiments, the fusion protein comprises or consists of an amino acid sequence shown in Table 7 below. [Table 10-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5] [Table 11-6] [Table 11-7] [Table 11-8]
[0092] As shown in Table 7 above, in some embodiments, the IgG Fc comprises a mouse IgG kappa signal sequence comprising the amino acid sequence METDTLLLWVLLLWVPGSTG (SEQ ID NO: 194). In some embodiments, a different signal sequence is used. In some embodiments, as shown in Table 7, no signal sequence is present on the fusion protein produced.
[0093] Other half-life extenders As used herein, the term "half-life extending moiety" includes non-proteinaceous half-life extending moieties, such as PEG or HES, and proteinaceous half-life extending moieties, such as an Fc domain. In some embodiments, a non-proteinaceous half-life extending moiety is linked to a fusion protein as described herein. In some embodiments, a non-proteinaceous half-life extending moiety is linked to a fusion protein in place of the IgG Fc. In some embodiments, a non-proteinaceous half-life extending moiety is linked to a fusion protein in addition to the IgG Fc.
[0094] Examples of suitable polymer molecules that function as non-proteinaceous half-life extending moieties include polymer molecules selected from the group consisting of polyalkylene glycols (PAGs), such as polyethylene glycol (PEG) and polypropylene glycol (PPG), branched PEGs, hydroxyalkyl starches (HAS), e.g., hydroxyethyl starch (HES), polysialic acid (PSA), poly-vinyl alcohol (PVA), poly-carboxylates, poly-(vinylpyrrolidone), polyethylene-co-maleic anhydride, polystyrene-co-maleic anhydride, dextran, including carboxymethyl-dextran, or any other biopolymer suitable for reducing immunogenicity and / or increasing functional in vivo half-life and / or serum half-life. Another example of a polymer molecule is human albumin or another abundant plasma protein. In general, polyalkylene glycol-derived polymers are biocompatible, non-toxic, non-antigenic, non-immunogenic, have various water solubility properties, and are easily excreted from the body.
[0095] PEG has the advantage of having few crosslinkable reactive groups, for example, compared to polysaccharides such as dextran.In particular, monofunctional PEG, for example, methoxypolyethylene glycol (mPEG), is interesting because its coupling chemistry is relatively simple (only one reactive group is available for conjugating with the linking group on the polypeptide).Therefore, the resulting conjugated fusion protein described herein is more homogeneous, as the risk of crosslinking is eliminated, and the reaction of the polymer molecule with the variant polypeptide is easier to control.
[0096] To effect covalent attachment of the polymer molecule(s) to the fusion protein described herein, the hydroxyl end groups of the polymer molecules must be provided in activated form, i.e., with reactive functional groups (examples of which include primary amino groups, hydrazide (HZ), thiol, succinate (SUC), succinimidyl succinate (SS), succinimidyl succinamide (SSA), succinimidyl propionate (SPA), succinimidyl butyrate (SBA), succinimidyl carboxymethylate (SCM), benzotriazole carbonate (BTC), N-hydroxysuccinimide (NHS), aldehyde, nitrophenyl carbonate (NPC), and tresylate (TRES)). Suitable activated polymer molecules are commercially available, for example, from Shearwater Polymers, Inc., Huntsville, Ala., USA, or PolyMASC Pharmaceuticals plc, UK.
[0097] Alternatively, the polymer molecules can be activated by conventional methods known in the art, such as those disclosed in WO 90 / 13540. Specific examples of activated linear or branched polymer molecules for use herein are described in the Shearwater Polymers, Inc. 1997 and 2000 Catalogs (Functionalized Biocompatible Polymers for Research and Pharmaceuticals, Polyethylene Glycol and Derivatives, incorporated herein by reference). Specific examples of activated PEG polymers include the following linear PEGs: NHS-PEG (e.g., SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM-PEG), as well as branched PEGs such as NOR-PEG, BTC-PEG, EPOXPEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG, and MAL-PEG, and PEG2-NHS, as well as those disclosed in U.S. Patent Nos. 5,932,462 and 5,643,575, both of which are incorporated herein by reference. Additionally, the following publications disclose useful polymer molecules and / or PEGylation chemistries:U.S. Patent No. 5,824,778, U.S. Patent No. 5,476,653, WO97 / 32607, EP229,108, EP402,378, U.S. Patent No. 4,902,502, U.S. Patent No. 5,281,698, U.S. Patent No. 5,122,614, U.S. Patent No. 5,219,564, WO92 / 16555, WO9 4 / 04193, WO94 / 14758, WO94 / 17039, WO94 / 18247, WO94 / 28024, WO95 / 00162, WO95 / 119 24, WO95 / 13090, WO95 / 33490, WO96 / 00080, WO97 / 18832, WO98 / 41562, WO98 / 48837, WO 99 / 32134, WO99 / 32139, WO99 / 32140, WO96 / 40791, WO98 / 32466, WO95 / 06058, EP439508, WO97 / 03106, WO96 / 21469, WO95 / 13312, EP921131, U.S. Patent No. 5,736,625, WO98 / 05363, EP 809996, U.S. Patent No. 5,629,384, WO 96 / 41813, WO 96 / 07670, U.S. Patent No. 5,473,034, U.S. Patent No. 5,516,673, EP 605963, U.S. Patent No. 5,382,657, EP 510356, EP 400472, EP 183503, and EP 154316.
[0098] Specific examples of activated PEG polymers that are particularly preferred for coupling to cysteine residues include the following linear PEGs: vinylsulfone-PEG (VS-PEG), preferably vinylsulfone-mPEG (VS-mPEG), maleimide-PEG (MAL-PEG), preferably maleimide-mPEG (MAL-mPEG), and orthopyridyl-disulfide-PEG (OPSS-PEG), preferably orthopyridyl-disulfide-mPEG (OPSS-mPEG). Typically, such PEG or mPEG polymers have a size of about 5 kDa, about 10 kDa, about 12 kDa or about 20 kDa.
[0099] Conjugation of the fusion proteins and activated polymer molecules described herein can be carried out by using any conventional method, for example as described in the following references, which also describe suitable methods for activating the polymer molecules: Harris and Zalipsky, eds., Poly(ethylene glycol) Chemistry and Biological Applications, AZC Washington; RF Taylor, (1991), "Protein immobilisation. Fundamental and applications," Marcel Dekker, NY; SSWong, (1992), "Chemistry of Protein Conjugation and Crosslinking," CRC Press, Boca Raton; GTHermanson et al., (1993), "Immobilized Affinity Ligand Techniques", Academic Press, NY.
[0100] Those skilled in the art will recognize that the activation method and / or conjugation chemistry used will depend on the attachment group(s) of the fusion protein (examples of which are further provided above), as well as the functional groups of the polymer (e.g., amine, hydroxyl, carboxyl, aldehyde, sulfhydryl, succinimidyl, maleimide, vinylsulfone, or haloacetate). PEGylation can be directed to conjugation to all available attachment groups on the fusion protein (i.e., those attachment groups exposed at the surface of the polypeptide), or to one or more specific attachment groups, such as the N-terminal amino group as described in U.S. Pat. No. 5,985,265, or to cysteine residues. Furthermore, conjugation can be accomplished in one step or in a stepwise manner (e.g., as described in WO 99 / 55377).
[0101] For PEGylation to cysteine residues (see above), the fusion protein is usually treated with a reducing agent such as dithiothreitol (DDT) prior to PEGylation. The reducing agent is then removed by any conventional method such as desalting. Conjugation of PEG to cysteine residues is typically carried out in a suitable buffer with a pH of 6-9 at various temperatures ranging from 4°C to 25°C for up to 16 hours.
[0102] It will be understood that PEGylation will be designed to generate an optimal molecule with respect to the number of PEG molecules attached, the size and shape of such molecules (e.g., whether they are linear or branched), and the attachment site(s) in the fusion protein. The molecular weight of the polymer used can be selected, for example, based on the desired effect to be achieved.
[0103] In connection with conjugation to only a single binding group on the fusion protein (e.g., the N-terminal amino group), it may be advantageous for the polymer molecule, which may be linear or branched, to have a high molecular weight, preferably about 10-25 kDa, for example about 15-25 kDa, for example about 20 kDa.
[0104] Usually, polymer conjugation is carried out under conditions that aim to react many of the available polymer binding groups with the polymer molecule. This is achieved by a suitable molar excess of polymer to polypeptide. Typically, the molar ratio of activated polymer molecule to polypeptide is up to about 1000-1, for example up to about 200-1, or up to about 100-1. However, in some cases, the ratio can be somewhat lower, such as up to about 50-1, 10-1, 5-1, 2-1, or 1-1, to obtain optimal reaction.
[0105] It is also contemplated that the polymer molecule is coupled to the fusion protein via a linker. Suitable linkers are well known to those skilled in the art. A preferred example is cyanuric chloride (Abuchowski et al., (1977), J. Biol. Chem., 252, 3578-3581; U.S. Pat. No. 4,179,337; Shafer et al., (1986), J. Polym. Sci. Polym. Chem. Ed., 24, 375-378).
[0106] Following conjugation, any remaining activated polymer molecules are blocked according to methods known in the art, for example, by adding a primary amine to the reaction mixture, and the resulting unactivated polymer molecules are removed by an appropriate method.
[0107] It will be understood that depending on the circumstances, e.g., the particular PEGylation conditions, including the amino acid sequence of the fusion protein, the nature of the activated PEG compound used, and the molar ratio of PEG to polypeptide, various degrees of PEGylation may be obtained, with higher degrees of PEGylation generally being obtained with higher ratios of PEG to fusion protein. However, the PEGylated fusion proteins resulting from any given PEGylation process will usually contain a stochastic distribution of conjugated fusion proteins having slightly different degrees of PEGylation.
[0108] To improve the biological half-life of the fusion proteins described herein, chemical modifications such as PEGylation or HESylation can be applied.
[0109] HAS and HES non-proteinaceous polymers and methods for producing HAS or HES conjugates are disclosed, for example, in WO02 / 080979, WO03 / 070772, WO057092391 and WO057092390.
[0110] Polysialylation is another technique that uses the natural polymer polysialic acid (PSA) to extend the half-life and improve the stability of therapeutic peptides and proteins. PSA is a polymer of sialic acid (sugar). When used for protein and therapeutic peptide drug delivery, polysialic acid provides a protective microenvironment upon conjugation. This increases the active life of the fusion protein in the circulation and prevents it from being recognized by the immune system. PSA polymers are found naturally in the human body. It was introduced by certain bacteria that evolved over millions of years to cover the walls. These naturally polysialylated bacteria were then able to compromise the body's defense system thanks to molecular mimicry. PSA, the ultimate natural stealth technology, can be easily produced from such bacteria in large quantities and with predetermined physical properties. Bacterial PSA is completely non-immunogenic, even when bound to proteins, because it is chemically identical to the human PSA.
[0111] Biological activity of relaxin-2 fusion proteins In some embodiments, the relaxin-2 fusion proteins described herein have an increased level of biological activity compared to native relaxin-2. In some embodiments, any of the relaxin-2 fusion proteins described herein have about 1% to about 200% of the biological activity compared to native relaxin-2. In some embodiments, the relaxin-2 fusion proteins have at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150%, about 175%, or about 200% of the biological activity compared to native relaxin-2.
[0112] In some embodiments, any of the relaxin-2 fusion proteins described herein have about 1% to about 200% of the maximal biological activity compared to native relaxin-2. In some embodiments, the maximal biological activity is the maximal response (E) of relaxin-2 or relaxin-2 fusion protein. maxIn some embodiments, the relaxin-2 fusion protein has at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150%, about 175%, or about 200% of the maximal biological activity compared to native relaxin-2.
[0113] In some embodiments, any of the relaxin-2 fusion proteins described herein have an enhanced potency of at least about 0.001-fold to at least about 1,000-fold compared to native relaxin-2. In some embodiments, potency is measured as the half-maximal response (EC 50 In some embodiments, the relaxin-2 fusion protein has at least about 0.001-fold, about 0.01-fold, about 0.1-fold, about 1-fold, about 10-fold, about 100-fold, or about 1,000-fold greater potency than native relaxin-2.
[0114] Biological activity can be any biological activity of natural relaxin-2. For example, biological activity can be the ability to bind to the receptor of natural relaxin-2, RXFP1. The binding of relaxin-2 to RXFP1 can be measured by any known method in the art, such as radioligand binding. In some embodiments, the fusion protein described herein binds to RXFP1 when RXFP1 is expressed on the cell surface.
[0115] In some embodiments, the biological activity can be the ability to activate RXFP1 on the cell surface. Activation of RXFP1 by the relaxin-2 fusion proteins described herein can be determined by an increase in cAMP using any method known in the art, such as measuring the activity of a cAMP-driven reporter gene, e.g., β-galactosidase. Activation of RXFP1 by the relaxin-2 fusion proteins described herein in cells can also be determined by using a biosensor, such as a GloSensor biosensor. Activation of RXFP1 by the relaxin-2 fusion proteins described herein in cells can also be determined by measuring the expression of a particular gene, such as the expression of angiogenic factors, e.g., VEGF, or MMPs, using methods known in the art. In some embodiments, the biological activity is a physiological, biochemical activity or any other effect-inducing activity of relaxin-2. Exemplary biological activities include, but are not limited to, vasodilation, collagen degradation, angiogenesis, lowering arterial blood pressure, increasing renal artery blood flow, increasing cardiac filling in diastole, resolving established fibrosis, and inhibiting the development of new fibrosis.
[0116] In some embodiments, the fusion proteins described herein have improved pharmacokinetic profiles. Without wishing to be bound by any theory, the structures of the fusion proteins described herein are based, at least in part, on the surprising discovery that lowering the pI of relaxin-2 fusion protein analogs increases their circulating half-life. In some embodiments, the circulating half-life is in a mammal. In some embodiments, the mammal is a rodent or a primate. In some embodiments, the rodent is a rat or a mouse. In some embodiments, the primate is a human or a monkey. In some embodiments, the monkey is a cynomolgus monkey. In some embodiments, the mammal is a human. In some embodiments, the fusion proteins described herein may have a circulating half-life of about 5 hours, 10 hours, 20 hours, 50 hours, 75 hours, 100 hours, 125 hours, 150 hours, or more. In some embodiments, the fusion proteins described herein may have a circulating half-life of 5-10 hours, 10-20 hours, 20-50 hours, 50-75 hours, 75-100 hours, 100-125 hours, or 125-150 hours. Values and ranges intermediate to the recited values are also intended to be part of the present disclosure. In some embodiments, the fusion proteins described herein have a longer circulating half-life than native two-chain relaxin-2. For example, the circulating half-life of native two-chain relaxin-2 may be less than about 5 hours. (See, e.g., Chen et al., The Pharmacokinetics of Recombinant Human Relaxin in Non-Pregnant Women after Intravenous, Intravaginal, and Intracervical Administration, Pharm. Res. 10:834038 (1993), incorporated herein by reference).
[0117] This is because the increased half-life may be due, at least in part, to the reduced pI of the fusion proteins described herein. In some embodiments, the pI of the fusion proteins is less than 9.4. In some embodiments, the pI of the fusion proteins is less than 9.0, 8.9, 8.8, 8.7, 8.6, 8.5, 8.4, 8.3, 8.2, 8.1, or 8.0. In some embodiments, the pI of the fusion proteins described herein is between 6.0 and 9.4. In some embodiments, the pI of the fusion proteins described herein is between 6.5 and 8.5, 6.6 and 8.4, 6.7 and 8.3, 6.8 and 8.2, 6.8 and 8.1, 6.8 and 8.0, or 6.8 and 7.9. In some embodiments, the pIs described above are calculated or theoretical pIs. In some embodiments, the pIs described above are experimentally determined pIs.
[0118] As used herein, "circulating half-life" refers to the time it takes for the plasma concentration of a drug to halve its steady state when circulating in the whole blood of an organism. The circulating half-life of a particular drug can vary depending on a number of factors, including but not limited to the drug's dosage, formulation, and / or route of administration. Those skilled in the art can determine the circulating half-life of a drug using methods well known in the art, such as the method described in Chen above.
[0119] vector The present disclosure also provides a nucleic acid molecule encoding any of the fusion proteins or peptides described herein. In some embodiments, the nucleic acid molecule described herein is a DNA molecule. In some embodiments, the nucleic acid molecule described herein is an RNA molecule.
[0120] The nucleic acid molecules described herein can be transcribed from a promoter in an expression vector. In some embodiments, the vector is a non-viral vector. Exemplary non-viral vectors include, but are not limited to, plasmid DNA, transposons, episomal plasmids, minicircles, ministrings, and oligonucleotides (e.g., mRNA, naked DNA). In some embodiments, the vector is a DNA plasmid vector.
[0121] In some embodiments, the vector is a viral vector. The viral vector may be replication-competent or replication-incompetent. The viral vector may be integrating or non-integrating. Several viral-based systems have been developed for gene transfer into mammalian cells, and a suitable viral vector may be selected by one skilled in the art. Exemplary viral vectors include, but are not limited to, adenoviral vectors (e.g., adenovirus 5), adeno-associated viral (AAV) vectors (e.g., AAV2, 3, 5, 6, 8, 9), retroviral vectors (MMSV, MSCV), lentiviral vectors (e.g., HIV-1, HIV-2), gamma retroviral vectors, herpes viral vectors (e.g., HSV1, HSV2), alphaviral vectors (e.g., SFV, SIN, VEE, M1), flavivirus (e.g., Kunjin, West Nile, Dengue virus), rhabdoviral vectors (e.g., rabies virus, VSV), measles viral vectors (e.g., MV-Edm), Newcastle disease viral vectors, pox viral vectors (e.g., VV), measles virus, and picornaviral vectors (e.g., coxsackie virus).
[0122] In some embodiments, a vector or expression cassette contains one or more additional elements, including, but not limited to, a promoter, an enhancer, a polyadenylation (polyA) sequence, and a selection gene.
[0123] In some embodiments, the vector comprises a polynucleotide sequence encoding an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence listed in any of Tables 1-7. In some embodiments, the vector comprises or consists of a nucleotide sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the nucleotide sequences listed in Table 8 below. [Table 11-1] [Table 12-2] [Table 12-3] [Table 12-4] [Table 12-5] [Table 12-6] [Table 12-7] [Table 12-8] [Table 12-9] [Table 12-10] [Table 12-11] [Table 12-12] [Table 12-13] [Table 12-14] [Table 12-15] [Table 12-16] [Table 12-17] [Table 12-18] [Table 12-19] [Table 12-20] [Table 12-21] [Table 12-22] [Table 12-23] [Table 12-24]
[0124] In some embodiments, any of the nucleotide sequences set forth in Table 8 further comprise additional nucleotide sequences at the 5' and / or 3' end. In some embodiments, any of the nucleotide sequences set forth in Table 8 further comprise the nucleotide sequence ACGGGACCGATCCAGCCTCCGGACTCTAGAGCCACC (SEQ ID NO: 185) at the 5' end and / or any of the nucleotide sequences set forth in Table 8 further comprise the nucleotide sequence TGATAAACCGGTTAGTAATGAGTTTGATATCTCGAC (SEQ ID NO: 186) at the 3' end.
[0125] Pharmaceutical Compositions The present disclosure provides pharmaceutical compositions comprising the fusion proteins or component peptides described herein, or nucleic acid molecules, or expression vectors encoding them. The pharmaceutical compositions described herein are formulated with suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerability, and the like. Many suitable formulations can be found in the formulary known to every pharmacist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (such as LIPOFECTIN™, Life Technologies, Carlsbad, CA), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
[0126] The dose of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein administered to a patient may vary depending on the age and size of the patient, the target disease, condition, route of administration, etc. The preferred dose is typically calculated according to body weight or body surface area. Depending on the severity of the condition, the frequency and duration of treatment can be adjusted. The effective dosage and schedule for administering the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, can be empirically determined, e.g., the progress of the patient can be monitored by periodic evaluation and the dosage adjusted accordingly. Furthermore, interspecies scaling of dosages can be performed using methods well known in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351).
[0127] Various delivery systems are known and can be used to administer the pharmaceutical compositions disclosed herein, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, such as by infusion or bolus injection, absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. Administration can be systemic or local.
[0128] Any pharmaceutical composition described herein can be delivered subcutaneously or intravenously using a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device facilitates application when delivering the pharmaceutical composition disclosed herein. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and easily replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, a disposable pen delivery device is pre-filled with a pharmaceutical composition held in a reservoir within the device. Once the reservoir is empty of pharmaceutical composition, the entire device is discarded.
[0129] In certain circumstances, pharmaceutical compositions can be delivered in controlled release systems. In one embodiment, pumps can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, polymeric materials can be used, see Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, controlled release systems can be placed in the vicinity of the target of the composition, thereby requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.
[0130] The injectable preparations may include dosage forms for intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, drip infusion, and the like. These injectable preparations may be prepared by publicly known methods. For example, the injectable preparations may be prepared by dissolving, suspending, or emulsifying any of the fusion proteins described herein in a sterile aqueous or oily medium that is conventionally used for injection. Aqueous media for injection include, for example, saline, isotonic solutions containing glucose, and other auxiliary agents, which may be used in combination with suitable solubilizing agents such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)]. As oily media, for example, sesame oil, soybean oil, and the like are used, which may be used in combination with solubilizing agents such as benzyl benzoate, benzyl alcohol, and the like. The injection solution thus prepared is preferably filled into a suitable ampoule.
[0131] Advantageously, the pharmaceutical composition for oral or parenteral use is prepared in a suitable unit dose dosage form to suit the dose of the active ingredient. Such unit dose dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the fusion protein contained is generally about 5 to about 500 mg per dosage form in a unit dose, and particularly in the form of injection, the fusion protein is preferably contained in an amount of about 5 to about 100 mg, and for other dosage forms, about 10 to about 250 mg.
[0132] therapeutic use Monotherapy The present disclosure provides a method comprising administering to a subject in need thereof a therapeutic composition comprising the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, as described herein. The therapeutic composition may comprise any of the fusion proteins or component peptides disclosed herein and a pharma- ceutically acceptable carrier or diluent. As used herein, the phrase "subject in need thereof" refers to a human or non-human animal exhibiting one or more symptoms or signs of a relaxin-2-associated disorder or disease, or otherwise benefiting from increased or decreased relaxin-2 activity. The fusion proteins or component peptides described herein, and expression vectors encoding them (and therapeutic compositions comprising the same) are useful, inter alia, for the treatment of any disease or disorder in which activation or inactivation of RXFP1 is beneficial.
[0133] In certain embodiments, the present disclosure provides a method for activating RXFP1 on a cell surface, comprising activating RXFP1 on the cell surface by administering to a subject in need thereof an effective amount of a fusion protein or component peptide, or a nucleic acid molecule, or an expression vector encoding the same, as described herein. Activation of RXFP1 on the cell surface can result in cellular responses, including, but not limited to, elevated cAMP levels, vasodilation, expression of angiogenic factors including VEGF, expression of MMPs, and collagen degradation. In some embodiments, the cells are selected from the group consisting of endothelial cells, vascular smooth muscle cells, other vascular cells, cardiomyocytes, other cardiac cells, and fibroblasts.
[0134] The present disclosure also provides methods for treating various relaxin-2 related diseases. As used herein, the term "relaxin-2 related disease" is a disease or disorder caused by or related to relaxin-2 protein production or relaxin-2 protein activity. The term "relaxin-2 related disease" includes diseases, disorders, or conditions that would benefit from increased relaxin-2 protein activity. Non-limiting examples of relaxin-2 related diseases include kidney disease, including but not limited to focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, hepatorenal syndrome, scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cardiac fibrosis, fibrosis, including but not limited to NASH, dilated cardiomyopathy, diastolic heart failure, pulmonary arterial hypertension, chronic heart failure, acute heart failure, congestive heart failure, coronary artery disease, hypertension, preeclampsia. Further details regarding the signs and symptoms of various diseases or conditions are provided herein and are well known in the art.
[0135] Administration of a composition according to the methods described herein may result in a reduction in the severity, signs, symptoms, or markers of a relaxin-2-related disease or disorder in a patient having a relaxin-2-related disease or disorder. "Reduction" in this context means a statistically significant reduction in such levels. The reduction (absolute reduction or reduction in the difference between elevated levels and normal levels in a subject) may be, for example, at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or less than the detection level of the assay used.
[0136] Combination Therapies and Formulations The present disclosure also provides compositions and therapeutic formulations comprising the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein in combination with one or more additional therapeutically active ingredients, and methods of treatment comprising administering such combinations to a subject in need thereof.
[0137] Exemplary additional therapeutic agents include any therapeutic agent that may be used to treat any of the relaxin-2 related disorders described herein. Exemplary additional therapeutic agents that may be combined or administered in combination with the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein include, but are not limited to, angiotensin II receptor blockers, such as azilsartan, candesartan, eprosartan, losartan, ACE inhibitors, such as lisinopril, benazepril, captopril, enalapril, moexipril, perindopril, quinapril, trandolapril, calcium channel blockers, such as amlodipine, ... lodipine and benazepril, amlodipine and valsartan, diltiazem, felodipine, isradipine, nicardipine, nimodipine, nisoldipine, verapamil, or diuretics such as chlorthalidone, hydrochlorothiazide, metolazone, indapamide, torsemide, furosemide, bumetanide, amiloride, triamterene, spironolactone, eplerenone, aldosterone antagonists such as spironolactone, eplerenone, digoxin such as lanoxin, beta blockers such as carvedilol, metoprolol, bisoprolol.
[0138] In some embodiments, the additional therapeutic agent is a drug effective for treating fibrosis, including but not limited to small molecule drugs and antibodies. Exemplary anti-fibrosis drugs include, but are not limited to, TGF-β inhibitors, such as small molecules such as hydronidone, distiertide, or antibodies such as fresolimumab, PDGF or VEGF antagonists, such as small molecules such as imatinib, nilotinib, or any drug that targets extracellular factors involved in the pathogenesis of fibrosis. A description of exemplary drugs for fibrosis can be found, for example, in Li et al., "Drugs and Targets in Fibrosis, Frontiers in Pharm." 8:Article 855 (2007), which is incorporated herein by reference.
[0139] The additional therapeutically active ingredient(s) may be administered immediately prior to, simultaneously with, or immediately following administration of the fusion proteins or component peptides described herein, or nucleic acid molecules, or expression vectors encoding them.
[0140] The present disclosure provides pharmaceutical compositions in which the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, as described herein, are co-formulated with one or more additional therapeutically active ingredient(s) as described elsewhere herein.
[0141] Dosing regimen In some embodiments, multiple doses of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein can be administered to a subject over a period of time. The method according to this aspect of the disclosure includes sequentially administering to a subject multiple doses of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein. As used herein, "sequentially administering" means that each dose of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, is administered to a subject at different times, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). The disclosure provides methods that include sequentially administering to a patient a single primary dose of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, followed by one or more secondary doses of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, optionally followed by one or more tertiary doses of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein.
[0142] The terms "primary dose", "secondary dose", and "tertiary dose" refer to the time sequence for administration of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein. Thus, a "primary dose" is the dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"), a "secondary dose" is the dose administered after the primary dose, and a "tertiary dose" is the dose administered after the secondary dose. The primary, secondary, and tertiary doses may all contain the same amount of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, but generally may differ from each other in terms of frequency of administration. However, in certain embodiments, the amount of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, contained in the primary, secondary, and / or tertiary doses differ from each other during the course of treatment (e.g., adjusted up or down as appropriate). In certain embodiments, two or more (e.g., two, three, four, or five) doses are administered at the start of the treatment regimen as a "loading dose," with subsequent doses administered on a less frequent basis (e.g., "maintenance doses").
[0143] In one exemplary embodiment, each secondary and / or tertiary dose is administered 1 to 26 (e.g., 1, 1 1 / 2, 2, 2 1 / 2, 3, 3 1 / 2, 4, 4 1 / 2, 5, 5 1 / 2, 6, 6 1 / 2, 7, 7 1 / 2, 8, 8 1 / 2, 9, 9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 The phrase "immediately preceding dose" as used herein means a dose of a fusion protein or component peptide, or nucleic acid molecule, or expression vector encoding the same, as described herein, in a series of multiple doses, which is administered to a patient prior to administration of the immediately following dose with no intervening doses.
[0144] Methods according to this aspect of the disclosure may include administering to a patient any number of secondary and / or tertiary doses of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein. For example, in certain embodiments, only a single secondary dose is administered to a patient. In other embodiments, two or more (e.g., two, three, four, five, six, seven, eight, or more) secondary doses are administered to a patient. Similarly, in certain embodiments, only a single tertiary dose is administered to a patient. In other embodiments, two or more (e.g., two, three, four, five, six, seven, eight, or more) tertiary doses are administered to a patient.
[0145] In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1-2 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2-4 weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and / or tertiary doses are administered to the patient may vary over the course of the treatment regimen. The frequency of administration may also be adjusted by the physician during the course of treatment depending on the needs of the individual patient after clinical testing.
[0146] In one embodiment, one or more of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, are administered to a subject as a weight-based dose. A "weight-based dose" (e.g., a dose in mg / kg) is a dose of a protein or peptide that varies with the weight of the subject.
[0147] In another embodiment, one or more of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein are administered to the subject as a fixed dose. A "fixed dose" (e.g., a dose in mg) means that one dose of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, is used for every subject, regardless of any particular subject-related factors, such as body weight. In one particular embodiment, the fixed dose of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, is based on a given weight or age.
[0148] In general, suitable doses of the fusion proteins or component peptides, or nucleic acid molecules described herein, or expression vectors encoding them, can be in the range of about 0.001 to about 200.0 milligrams per kilogram of recipient body weight, generally in the range of about 1 to 50 mg per kilogram of body weight. For example, the fusion proteins or component peptides, or nucleic acid molecules described herein, or expression vectors encoding them, can be administered at about 0.1 mg / kg, about 0.2 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 1.5 mg / kg, about 2 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg per single dose. Values and ranges intermediate to the recited values are also intended to be part of this disclosure.
[0149] In some embodiments, one or more of the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, are administered as a fixed dose of about 10 mg to about 2500 mg. In some embodiments, the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein, are administered as a fixed dose of about 10 mg, about 15 mg, about 20 mg, 25 mg, about 30 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 440 mg, about 460 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 820 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 g, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1500 mg, about 2000 mg, or about 2500 mg. Values and ranges intermediate to the recited values are also intended to be part of this disclosure.
[0150] kit Any of the compositions described herein can be included in a kit. In a non-limiting example, the kit includes one or more of the fusion proteins or component peptides described herein, or nucleic acid molecules, or expression vectors encoding them.
[0151] The kit may further include reagents or instructions for using the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, described herein in a subject. It may also include one or more buffers.
[0152] The components of the kits may be packaged in either aqueous media or lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe, or other container means into which the components may be placed, and preferably suitably aliquoted. Where there is more than one component in the kit (wherein the labeling reagent and label may be packaged together), the kit will also generally include a second, third, or other additional container into which the additional components may be placed separately. The kits may also include a second container means for containing a sterile, pharma- ceutically acceptable buffer and / or other diluent. However, various combinations of components may be included in the vial. The kits of the present disclosure will also typically include a means for containing the fusion proteins or component peptides, or nucleic acid molecules, or expression vectors encoding them, as described herein, and any other reagent containers in close confinement for commercial sale.
[0153] When the components of the kit are provided in one or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. However, the components of the kit may be provided as dry powder(s). When the reagents and / or components are provided as dry powders, the powders can be reconstituted by adding a suitable solvent. It is envisioned that the solvent may also be provided in another container means. EXAMPLES
[0154] The presently disclosed embodiments are provided by way of illustration and description and are not intended to limit the scope of the present disclosure.
[0155] Example 1. Heparin chromatography for relaxin-2 fusion protein analogs Introduction Heparin chromatography is a method commonly used in early candidate screening to better understand the tendency of a molecule to interact with elements of the vasculature when administered to a patient. Heparin and heparin sulfate proteoglycans are negatively charged polysaccharides present in the vasculature and tissues, to which positively charged molecules can bind at physiological pH (i.e., pI>7.4). Here, heparin chromatography was used to screen for candidates / variants with reduced heparin binding, which predicts favorable PK properties. Materials used for heparin chromatography are provided in Table 9. [Table 12]
[0156] method Mobile phase A (binding): 20mM Tris pH7.4 Mobile phase B (elution): 20mM Tris pH7.4 + 1M NaCl Injection: 10μg Detection: 220nm 1. Prior to analysis, the heparin column was equilibrated with mobile phase A at 0.5 mL / min for 10 min. 2. Samples for analysis were diluted to 1 mg / mL in 20 mM Tris pH 7.4 to minimize ionic strength. 3. The heparin chromatography method was performed on an Agilent HPLC using the gradient shown in Table 10 below. [Table 13] 4. A positive control (no heparin binding, human IgG pool) and a negative control (SE301 or AT1R) were included. 5. Samples were analyzed for retention time and relative retention time reported compared to the positive control (i.e., RT sample / RT positive control). 6. The approximate concentration of NaCl required for elution was calculated using the following calculation: [NaCl] = (RT sample-1) * 100
[0157] The results of the calculations are shown in Table 11. [Table 14]
[0158] result Table 12 shows the heparin chromatography results for various relaxin-2 analog fusion proteins. [Table 15] *Experimentally determined using imaged capillary isoelectric focusing.
[0159] The IgG is from Jackson ImmunoResearch (catalog number 009-000-003). The "previous fusion protein" is a LALA IgG-RelB-linker-RelA fusion with a theoretical pI of 8.5, but an experimentally determined pI of 9.4. The linker protein contains only one acidic amino acid. SEQ ID NOs: 53, 56, 58, 59, and 61-64 have a linker protein that contains at least two acidic amino acids, as well as LALA IgG (SEQ ID NO: 50 or 201). The last two fusion proteins have a linker protein that contains only one acidic amino acid and have a higher theoretical pI. As shown in Table 12 above, there is a correlation between the lower pI found through heparin chromatography and lower nonspecific binding.
[0160] Example 2. Low pI relaxin-2 fusion protein analogs tend to reduce self-association as measured by affinity capture self-interaction nanoparticle spectroscopy (AC-SINS). Introduction When assessing the biophysical properties of development candidates, it is important to understand the tendency of a molecule to self-associate. The tendency of a molecule to self-associate can be assessed by concentrating the molecule to high concentration and assessing it by SEC (% monomer) or by measuring the change in turbidity (OD340nm) and the second virial coefficient (B) using DLS. 22 ) or the self-interaction coefficient (k d ) or AC-SINS(Δλ max There are many methods for using plasmon capture (AAC-SINS). All three of these methods provide useful information but use different amounts of material to perform the evaluation. AC-SINS has emerged as a high throughput method for evaluating self-association using minimal materials, but still gives high localized concentration by using affinity capture on gold nanoparticles. In short, gold nanoparticles are pre-coated with anti-human antibodies (Fc, Fab and H+L) which, when incubated with the target antibody in dilute solution, captures the antibody of interest and concentrates it in solution. When the immobilized molecules of interest interact, the interparticle distance between the gold nanoparticles decreases, resulting in an increased plasmon wavelength (i.e., red shift) that can be quantified using UV-VIS spectroscopy. The materials used for spectroscopy are provided in Table 13. [Table 16]
[0161] method Preparation of buffer solutions To prepare 20 mM sodium acetate pH 4.3, 2 mL of 1 M sodium acetate pH 4.3 stock was diluted to 100 mL with MilliQ water. The pH was measured at 4.3 ± 0.1 and the solution was sterile filtered. The solution remained stable at room temperature for one month.
[0162] To 1 g of PEG methyl ether thiol, 10 mL of MilliQ water was added. This was vortexed briefly to suspend the solids and create a 50 mM solution. To prepare a 10 μM solution for the final dilution, the following dilution scheme was followed: a. Dilute the 50 mM stock to 1 mM (20 μL of 50 mM stock + 980 μL of MilliQ water) b. Dilute the 1 mM step to 100 μM (10 μL of 1 mM stock + 90 μL of MilliQ water) c. Dilute the 100 μM step to 10 μM (100 μL of 100 μM stock + 900 μL of MilliQ water) d. Volumes can be scaled depending on the number of samples to be assayed e. The remaining 50 mM stock should be aliquoted and kept at -20°C until needed.
[0163] Preparation of gold nanoparticle solutions Goat anti-human Fc IgG antibody (capture) and goat IgG antibody (non-capture) were buffer exchanged into 20 mM sodium acetate, pH 4.3. After buffer exchange, the concentration of both antibodies was normalized to 0.4 mg / mL.
[0164] A 4:1 volume ratio mixture of capture (anti-Fc):non-capture (goat IgG) solutions was prepared for an 80% capture capacity coating solution used to incubate gold nanoparticles (AuNPs).
[0165] A 9:1 volume ratio of AuNP:coating solution was made. The solution was incubated overnight at room temperature in the dark.
[0166] After incubation, thiolated PEG was added to a final concentration of 0.1 μM from a diluted 10 μM stock to block vacant sites on the AuNPs (i.e., 5 mL of AuNP solution was added to 50 μL of 10 μM stock) and incubated in the dark for 1 h at room temperature.
[0167] Preparation of AuNP solution 2 mL of the coated AuNP solution was centrifuged at 20,000 × g for 15 min to precipitate the AuNPs, and 1800 μL of the supernatant was carefully removed using a 1 mL pipette. The pelleted AuNPs were gently resuspended using a 200 μL pipette to generate a 10x concentrated stock of coated AuNPs.
[0168] Preparation of target antibody solution (follow this for both methods) For each sample analyzed, 10 μL of AuNP concentrate was incubated with 100 μL of antibody test solution (normalized to 0.05 mg / mL) in 96-well polypropylene plates for 2 h in the dark at room temperature. For the purpose of blanking the assay and determining the wavelength shift upon addition of test antibody, two blank solutions were prepared with 10 μL of 10× AuNP concentrated in 100 μL of PBS. Ganitumab was included as a positive control (high association, red shift) and panitumumab as a negative control (non-associated, no UV shift). Each sample was prepared in duplicate for analysis.
[0169] After 2 hours of incubation, 100 μL of the resulting solution was transferred to a UV-transparent polystyrene plate (384-well format). Two blank solutions were transferred to properly assess the wavelength shift, and then duplicate standards and samples were added for analysis. The plate was then centrifuged at 1000×g for 1 minute to level the solutions in the wells.
[0170] Absorbance data is collected from 510 nm to 570 nm in 2 nm steps to determine the wavelength shift for each sample compared to AuNPs alone.
[0171] result The results from ASCINS are shown in Table 14 below. [Table 17]
[0172] As shown in Table 14 above, fusion proteins with low pI also have a reduced tendency to exhibit self-aggregation.
[0173] Example 3. Relaxin-2 fusion protein analogs induce cAMP responses in RXFP1 transfected cells method HEK293 cells were seeded in 96-well tissue culture plates and subsequently transiently co-transfected with human RXFP1 and pGloSensor-22F plasmids. Transfected cells were stimulated with relaxin-2 or its fusion protein analogue to induce Gs-mediated cAMP signaling. cAMP was assayed using the activity of the GloSensor biosensor, a mutant luciferase fused to a cAMP-binding domain, leading to the production of light in the presence of its substrate luciferin. This relative light unit (RLU) readout is used as a proxy for the cAMP response. reagent 96-well tissue culture treated plates. White with clear bottom. (Corning #3610) ·HEK293 cells (ATCC CRL-1573) Poly-D-lysine (Gibco A3890401) DPBS (calcium-free, magnesium-free, Gibco 14190250) DMEM (high glucose with L-glutamine and sodium pyruvate; Gibco 11995065) ·TrypLE Express(Gibco 12605010) FBS (HyClone™, Australian source; Cytiva SH30084) Penicillin-streptomycin (Gibco 15140122) ·CO2 independent medium (Gibco 18045088) ·Opti-MEM(TM) I reduced serum medium (Gibco 31985062) pGloSensor™-22F cAMP Plasmid (Promega Catalog No. E2301) D-Luciferin, potassium salt (GoldBio LUCK-1G) FuGENE HD Transfection Reagent (Promega number E2311) Reservoir (Corning / Axygen RES-V-25-SI) Relaxin-2 (R&D Biosystems 6586-RN-025) RXFP1-containing plasmid (pcDNA5 / FRT / TO-human RXFP1, full length) Forskolin (Sigma F6886) A plate reader capable of reading luminescence (CLARIOstar Plus)
[0174] Preparation of reagents D-Luciferin, potassium salt: D-Luciferin was reconstituted in 10 mM HEPES, pH 7.5 at 25 mg / mL (78.5 mM; MW = 318.4), aliquoted into disposable aliquots of approximately 200-500 µL in sterile microfuge tubes and stored at -80 °C.
[0175] Relaxin-2 peptide: Sterile DPBS (MW=5,986Da, ε=12,865M -1 cm -1 ) and reconstitute the relaxin-2 peptide or relaxin-2 fusion protein analog at 0.1 mg / mL in A 280 The final concentration was determined by measuring the concentration at RT. Aliquots were stored at -20°C.
[0176] Forskolin: Forskolin was reconstituted in 100% DMSO at 5 mM (2.05 mg / mL, MW=410.5). Aliquots were stored at -20°C.
[0177] cAMP Assay Medium: CO2-independent medium was pre-warmed to 37°C using a bead bath. A single aliquot of D-luciferin was thawed and added to a final concentration of 5% (e.g., 4.75 mL cAMP assay medium + 250 μL D-luciferin stock; yielding a final D-luciferin of 1.25 mg / mL or 3.93 mM). This was used within the same day or discarded.
[0178] Cell Culture and Maintenance HEK293 cells (ATCC CRL-1573) were cultured in DMEM + 10% FBS, 1% (1X or 10 U / mL) Pen-Strep in a humidified CO2 incubator at 37 C, 5% CO2 to 80-100% confluency. Cells were typically split 1:6 for 3 days and maintained in sterile T-75 tissue culture flasks.
[0179] cAMP Signaling Assay Protocol This protocol is adapted from the GloSensor cAMP assay by Promega.
[0180] Raw data was exported to Excel using MARS data analysis software opened after run on the CLARIOstar plate reader. These values are measured in RLU, or relative luminescence units.
[0181] As shown in Table 15, all of the low pI relaxin-2 fusion protein analogs were able to induce a cAMP response in RXFP1 transfected cells. [Table 18]
[0182] Example 4. In vitro characterization of relaxin-2 fusion protein analogs method Heparin Chromatography: Heparin chromatography was performed to understand the propensity of relaxin-2 fusion protein analogs to interact with elements of the vasculature and / or distribute rapidly to tissues when administered to patients. Analogs found to bind weakly to heparin may predict good pharmacokinetic properties. Briefly, prior to analysis, the heparin column was equilibrated at 0.5 mL / min for 10 minutes using mobile phase A (20 mM Tris pH 7.4). 10 μg per sample was run using the heparin chromatography method on an Agilent HPLC with detection at 280 nm using the gradient shown in Table 16 below (mobile phase B: 20 mM Tris pH 7.4, 1 M NaCl): [Table 19] A positive control (no heparin binding, pembrolizumab) and a negative control (lightly heparin binding, adalimumab) were included and samples were analyzed for retention time and relative retention time compared to the positive control (i.e., RT sample / RT positive control). The approximate concentration of NaCl required for elution was calculated using the following calculation: [NaCl] = (room temperature sample) x 100 The results of the calculations are shown in Table 17. [Table 20]
[0183] Capillary Isoelectric Focusing (cIEF) Imaged capillary isoelectric focusing (cIEF) was used to separate differentially charged molecules (i.e., relaxin-2 fusion protein analogs) using electrophoretic mobility in ampholyte solutions to determine their isoelectric points (pI). Molecules were loaded into a capillary and separated based on their pI by allowing them to migrate along an electric field until they reached a pH corresponding to their pI. UV absorbance across the capillary was measured throughout the separation, allowing real-time observation and eventual quantification.
[0184] Baculovirus particle (BVP) ELISA The BVP ELISA was used to understand the propensity of relaxin-2 fusion protein analogs for non-specific or non-target interactions. BVPs are empty viral capsids that do not carry the viral genome, but during the process of production, they can take components of the cell membrane with them by budding from the cell membrane. Thus, BVPs have a highly diverse cell surface with many moieties that mimic what the molecule of interest (i.e., relaxin-2 fusion protein analogs) may encounter in vivo. Briefly, BVP is coated onto plates by adding 25 μL of BVP solution to each well. BVP solution is made by diluting BVP stock (Medna Scientific; catalog number E3001) to 1 × 10 with 0.1 M carbonate buffer, pH 9.6. 6PFU / mL. After overnight incubation at 5°C, the BVP solution was blotted from the wells and the wells were washed three times with PBST. The plate was blocked with 100 μL / well of 1×BSA in PBS blocking buffer (Cepham Life Sciences; Cat. No. 10615). The plate was incubated for 1 hour on a plate shaker at 25°C. The blocking solution was blotted from the wells and the wells were washed three times with PBST. Samples (i.e., relaxin-2 fusion protein analogs) were prepared in duplicate to cover a dilution range from 3 μM to 0.1 nM and added to the plate. The plate was incubated for 1 hour at 25°C, after which the wells were blotted and washed three times with PBST. 25 μL / well of 1:10,000 diluted detection monoclonal antibody (Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific; Jackson ImmunoResearch; Catalog No. 50-194-1564) was added and the plate was incubated for 1 hour at 25° C., after which the wells were blotted and washed three times with PBST. 1-Step™ Ultra TMB-ELISA Substrate Solution (Life Technologies, Catalog No. 34029) was then added. After approximately 2 minutes, 25 μL of 2N HCl was added to quench the reaction and the plate was analyzed at 450 nm with correction at 570 nm using a plate reader.
[0185] Potency assay Transient hRXFP1 assays were performed essentially as described in Example 3.
[0186] Affinity capture self-interacting nanoparticle spectroscopy (AC-SINS) AC-SINS was performed to understand the tendency of molecules (i.e., relaxin-2 fusion protein analogs) to self-associate. The methodology performed was similar to that described in Example 2. AuNP solutions were prepared as follows: 1.5 mL of the coated AuNP solution was centrifuged at 20,000×g for 5 min to precipitate the AuNPs, and 1,350 μL was carefully removed using a 1 mL pipette. The pelleted AuNPs were gently resuspended using a 200 μL pipette to generate a 10x concentrated stock of coated AuNPs. For each sample analyzed, 5 μL of AuNP concentrate was incubated with 45 μL of antibody test solution (normalized to 0.05 mg / mL) in a 384-well polypropylene plate for 2 hours at room temperature in the dark. After 2 hours of incubation, absorbance data was collected from 450 nm to 650 nm in 1 nm steps to determine the wavelength shift for each sample compared to AuNPs alone.
[0187] Nanoscale Differential Scanning Fluorescence (NanoDSF) NanoDSF was performed using a NanoTemper Prometheus Panta to investigate the conformational stability of relaxin-2 protein fusion analogs. Structural stability was measured by applying a thermal lamp to a solution containing the molecule of interest and measuring intrinsic fluorescence, measuring backscattering, and using dynamic light scattering (DLS) to provide various thermal stability parameters.
[0188] result The results are shown in Table 18 below. [Table 21-1] [Table 22-2]
[0189] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
[0190] All references (e.g., publications or patents or patent applications) cited in this specification are incorporated by reference in their entirety for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
[0191] Other embodiments are within the scope of the following claims.
Claims
1. From the N-terminus to the C-terminus, A first peptide; A linker peptide; a second peptide, (a) the first peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO: 7, and the second peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO: 9; or The first peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO: 9, and the second peptide comprises an amino acid sequence that differs in 0, 1, 2, 3, 4, or 5 amino acids compared to the amino acid sequence of SEQ ID NO: 7, (b) the linker peptide comprises an amino acid sequence having 12-15 amino acids, including 2-5 acidic amino acids and 10-13 non-acidic amino acids; (c) a fusion protein, wherein the fusion protein has a pI of 6.0 to 8.
2.
2. the linker peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 195-199; R 1 is a non-acidic amino acid, R 2 The fusion protein of claim 1 , wherein is an acidic amino acid.
3. 3. The fusion protein of claim 1 or 2, wherein the acidic amino acid(s) is aspartate or glutamate.
4. The fusion protein of any one of claims 1 to 3, wherein the acidic amino acid(s) is glutamate.
5. The fusion protein of any one of claims 1 to 4, wherein the non-acidic amino acid(s) is / are glycine, proline, or serine.
6. The fusion protein of any one of claims 1 to 5, wherein the non-acidic amino acid(s) is glycine.
7. The fusion protein of any one of claims 1 to 6, wherein the linker peptide comprises one or more amino acid sequences of SEQ ID NOs: 14, 15, 16, 17, or 18.
8. The fusion protein according to any one of claims 1 to 7, wherein the linker peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 23.
9. The first peptide comprises the amino acid sequence of SEQ ID NO:3, 3 is methionine, lysine, or glutamine; X 4 The fusion protein according to any one of claims 1 to 8, wherein is methionine or lysine.
10. The first peptide comprises the amino acid sequence of SEQ ID NO: 4, 5 is arginine or absent, X 6 is leucine or aspartic acid, X 7 The fusion protein according to any one of claims 1 to 8, wherein is arginine, glutamine, or glutamate.
11. The second peptide comprises the amino acid sequence of SEQ ID NO:3, 3 is methionine, lysine, or glutamine; X 4 The fusion protein according to any one of claims 1 to 8 or 10, wherein is methionine or lysine.
12. The second peptide comprises the amino acid sequence of SEQ ID NO:4, 5 is arginine or absent, X 6 is leucine or aspartate, X 7 The fusion protein according to any one of claims 1 to 9, wherein is arginine, glutamine, or glutamate.
13. The fusion protein of any one of claims 1 to 9 or 12, wherein the first peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 7.
14. The fusion protein of any one of claims 1 to 8, 10, or 11, wherein the second peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 7.
15. The fusion protein of any one of claims 1 to 8, 10, 11, or 14, wherein the first peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 13.
16. The fusion protein of any one of claims 1 to 9, 12, or 13, wherein the second peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 13.
17. the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:8; the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:9; the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:10; or the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:11; or the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:12; or the first peptide comprises the amino acid sequence of SEQ ID NO:5 and the second peptide comprises the amino acid sequence of SEQ ID NO:13; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:8; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:9; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:10; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:11; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:12; or the first peptide comprises the amino acid sequence of SEQ ID NO:6 and the second peptide comprises the amino acid sequence of SEQ ID NO:13; or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:8; or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:9; or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:10; or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:11; or the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:12; or 17. The fusion protein of any one of claims 1 to 9, 12, 13, or 16, wherein the first peptide comprises the amino acid sequence of SEQ ID NO:7 and the second peptide comprises the amino acid sequence of SEQ ID NO:
13.
18. the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:8; or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:9; or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:10; or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:11; or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:12; or the second peptide comprises the amino acid sequence of SEQ ID NO:5 and the first peptide comprises the amino acid sequence of SEQ ID NO:13; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:8; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:9; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:10; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:11; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:12; or the second peptide comprises the amino acid sequence of SEQ ID NO:6 and the first peptide comprises the amino acid sequence of SEQ ID NO:13; or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:8; or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:9; or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:10; or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:11; or the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:12; or The fusion protein of any one of claims 1 to 8, 10, 11, 14, or 15, wherein the second peptide comprises the amino acid sequence of SEQ ID NO:7 and the first peptide comprises the amino acid sequence of SEQ ID NO:
13.
19. The fusion protein of any one of claims 1 to 9, 12, 13, 16, or 17, wherein the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 25 to 48.
20. The fusion protein of any one of claims 1 to 19, further comprising an IgG Fc.
21. The fusion protein of claim 20 , wherein the IgG Fc comprises the amino acid alanine at EU positions 234 and 235.
22. 22. The fusion protein of claim 20 or 21, wherein the IgG Fc comprises the amino acid alanine at EU position 329.
23. The fusion protein of any one of claims 20 to 22, wherein the IgG Fc comprises the amino acid alanine at EU positions 234, 235, and 329.
24. The fusion protein of any one of claims 20 to 23, wherein the IgG Fc comprises the amino acids alanine, alanine, alanine, leucine, and serine at EU positions 234, 235, 329, 428, and 434, respectively.
25. The fusion protein of any one of claims 20 to 23, wherein the IgG Fc comprises the amino acids lysine, phenylalanine, and tyrosine at EU positions 433, 434, and 436, respectively.
26. The fusion protein of any one of claims 20 to 25, wherein the IgG Fc comprises the amino acids tyrosine, threonine, and glutamate at EU positions 252, 254, and 256, respectively.
27. The fusion protein of any one of claims 20 to 26, wherein the IgG Fc comprises the amino acids leucine and serine at EU positions 428 and 434, respectively.
28. The fusion protein of claim 20 , wherein the IgG Fc comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of a human IgG1 Fc.
29. 29. The fusion protein of claim 28, wherein the IgG Fc comprises the amino acid sequence of a human IgG1 Fc.
30. 30. The fusion protein of claim 29, wherein the IgG Fc comprises an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-52 and 201-203.
31. 30. The fusion protein of claim 29, wherein the IgG Fc comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-52 and 201-203.
32. The fusion protein of any one of claims 20 to 31, wherein the IgG Fc is linked to the N-terminus of the first peptide.
33. The fusion protein of any one of claims 20 to 31, wherein the IgG Fc is linked to the C-terminus of the second peptide.
34. 20. The fusion protein of any one of claims 1 to 9, 12, 13, 16, 17, or 19, wherein the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-85 and 204-211.
35. 20. The fusion protein of any one of claims 1 to 9, 12, 13, 16, 17, or 19, wherein the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 86-118 and 214-221.
36. The fusion protein according to any one of the preceding claims, wherein the first and second peptides do not comprise the amino acid sequence of a peptide selected from the group consisting of SEQ ID NOs: 187-190.
37. A fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-118 and 204-225.
38. A polynucleotide comprising a nucleotide sequence encoding the fusion protein of any one of claims 1 to 37.
39. 39. The polynucleotide of claim 38, wherein the polynucleotide is an RNA molecule.
40. 39. The polynucleotide of claim 38, wherein the polynucleotide is a DNA molecule.
41. An expression vector comprising the polynucleotide according to any one of claims 38 to 40.
42. 42. The expression vector of claim 41, wherein the expression vector is a plasmid.
43. 42. The expression vector of claim 41, wherein the expression vector is a viral vector.
44. A host cell comprising a polynucleotide according to any one of claims 38 to 40 or an expression vector according to claim 41 or 42.
45. The host cell of claim 44, wherein the host cell is a prokaryotic cell.
46. The host cell of claim 44, wherein the host cell is a eukaryotic cell.
47. 46. The host cell of claim 45, wherein the prokaryotic cell is an E. coli cell or a Bacillus cell.
48. 47. The host cell of claim 46, wherein the eukaryotic cell is selected from the group consisting of a yeast cell, an insect cell, and a mammalian cell.
49. 49. The host cell of claim 48, wherein the mammalian cell is selected from the group consisting of a CHO cell, a HeLa cell, and a 293 cell.
50. 50. A population of cells comprising two or more of the host cells of any one of claims 44 to 49.
51. A method of producing a fusion protein according to any one of claims 1 to 37, comprising culturing a host cell according to any one of claims 44 to 49 under conditions such that said fusion protein is produced.
52. A pharmaceutical composition comprising an effective amount of a fusion protein according to any one of claims 1 to 37, or a polynucleotide according to any one of claims 38 to 40, or an expression vector according to any one of claims 41 to 43.
53. 38. A method for enhancing relaxin-2 associated activity in a primary cell, comprising contacting said primary cell with a fusion protein according to any one of claims 1 to 37, thereby enhancing relaxin-2 associated activity in said cell.
54. 54. The method of claim 53, wherein the fusion protein activates the relaxin-2 receptor (RXFP1) on the cell surface.
55. 55. The method of claim 53 or 54, wherein the method increases cAMP levels, induces vasodilation, induces expression of angiogenic factors, induces expression of MMPs, and induces collagen degradation in the primary cells.
56. 56. The method of any one of claims 53 to 55, wherein the primary cells are selected from the group consisting of endothelial cells, vascular smooth muscle cells, other vascular cells, cardiomyocytes, other cardiac cells, and fibroblasts.
57. The method of any one of claims 53 to 56, wherein the primary cells are in a subject.
58. 58. The method of claim 57, wherein the subject has a relaxin-2 associated disorder.
59. 59. The method of claim 58, wherein the relaxin-2 associated disorder is selected from the group consisting of a renal disease, a fibrotic disease, and a cardiovascular disease.
60. 60. The method of claim 59, wherein the disorder is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, hepatorenal syndrome, scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cardiac fibrosis, NASH, dilated cardiomyopathy, diastolic heart failure, pulmonary arterial hypertension, chronic heart failure, acute heart failure, congestive heart failure, coronary artery disease, hypertension, and pre-eclampsia.
61. 52。 A method of treating a relaxin-related disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a fusion protein of any one of claims 1 to 37, a polynucleotide of any one of claims 38 to 40, an expression vector of any one of claims 41 to 43, or a pharmaceutical composition of claim 52, thereby treating the relaxin-related disorder.
62. 62. The method of claim 61, wherein the relaxin-2 associated disorder is selected from the group consisting of a renal disease, a fibrotic disease, and a cardiovascular disease.
63. 63. The method of claim 62, wherein the disorder is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, hepatorenal syndrome, scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cardiac fibrosis, NASH, dilated cardiomyopathy, diastolic heart failure, pulmonary arterial hypertension, chronic heart failure, acute heart failure, congestive heart failure, coronary artery disease, hypertension, and preeclampsia.
64. 64. The method of any one of claims 61 to 63, wherein the method reduces arterial pressure, increases renal artery blood flow, increases cardiac filling during diastole, resolves established fibrosis, or inhibits the development of new fibrosis.
65. A kit comprising an effective amount of a fusion protein according to any one of claims 1 to 37, a polynucleotide according to any one of claims 38 to 40, an expression vector according to any one of claims 41 to 43, or a pharmaceutical composition according to claim 52, and instructions for use.
Citation Information
Patent Citations
Relaxin fusion polypeptide and its use
JP2014522641A
Modified polypeptides with increased duration of action and reduced immunogenicity.
JP2014527405A
Relaxin fusion polypeptides and uses thereof
JP2020505029A
Multivalent antibody analogs, and methods of their preparation and use
US20140377269A1
Relaxin immunoglobulin fusion proteins and methods of use
WO2017100540A2
